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ABSTRACT 
The progression from dermatitis in infancy to asthma and allergy in childhood has 
been termed the “atopic march”. Upper respiratory infections (URIs) in infancy are 
also linked to allergy and asthma. Human milk feeding and higher intakes of 
docosahexaenoic acid (DHA) may be protective. For the study, URIs and dermatitis 
in infancy were recorded and compared to human milk and DHA intake for 50 
healthy term infants born to women enrolled in a study of DHA supplementation 
during pregnancy. All had 24-hour dietary recalls at 6 wk, 4, 6, 9, and 12 months, first 
year medical records, and information about environmental factors related to 
allergy/asthma.  Forty-one of 50 received at least some human milk. DHA intake was 
estimated from individual milk (determined by chromatography) and formula DHA 
concentrations.  Most infants had one or more episodes of dermatitis (26/50) and URI 
(39/50). Duration of human-milk feeding in infancy was associated with fewer 
dermatitis episodes (R = -0.289, p = 0.044). Breast feeding for >16 wks vs. <16 wks 
appeared to result in later onset but not statistically fewer total first year URIs (p= 
0.611). With approximately 25% of the expected final sample complete, we find 
evidence already that longer human milk feeding may offer some protection against 
the “atopic march”. 
 
 
 
iv 
 
ACKNOWLEDGEMENTS 
 I would like to thank my mentor Dr. Carlson for all of your guidance and 
support through this process. I could not have completed this without your 
encouragement and enthusiasm. Talking with you in your office always made me feel 
like I could do anything if I put in the time and dedication.  I cannot thank you 
enough for the many hours spent working with me on this project.  I would also like 
to thank Dr. Gajewski for all your help and guidance with the statistical analysis. I 
learned a lot and am very appreciative of your support. In addition, I would like to 
thank my thesis committee members, Dr. Sullivan and Dr. Goetz for your 
encouragement and commitment to this thesis. I would also like to thank the Infant 
Nutrition Clinic Team, Laura Minns, Jocelynn Jacoby, Jill Shaddy and Beth Kerling 
for answering my infinite questions and guiding me in the right direction. Beth, you 
have been a huge support and I do not know how I would have survived this past year 
without you.  Finally, I would like to thank my family and friends for your support 
and encouragement and answering the late night phone calls. Thank you to my fiance´ 
for your unlimited dedication and encouragement even on the longest of days and 
latest of nights.  
 
 
 
v 
 
TABLE OF CONTENTS 
Glossary…………………………………………………………………………….ix 
Chapter  
1. Introduction……………………………………………………..……1 
Summary of Relevant Literature…….......................................1 
Justification for Further Investigation…………………………8 
Statement of Purpose……………………………………….....9 
Research Questions…………………………………………..10 
2. Review of Literature 
What is Immunity?..................................................................11 
Abnormal Immune Response: Allergy and Atopy…………..16 
Normal and Abnormal Immunity in Development…………..19 
Relationship between Intrauterine Environment and Later   
Allergy or Atopy……………………………………………..20 
Protective Factors of Human Milk…………………………...24 
Long Chain Polyunsaturated Fatty Acids and Infant Immune 
System………………………………………………………..31 
DHA and EPA Supplementation in Human Milk……………34 
Environmental Factors Affecting Infants Immune System….36 
 
 
vi 
 
3. `Methods 
Overview…………………………………………………….41 
Setting……………………………………………………….42 
Subjects……………………………………………………...43 
Data Collection 
 Primary Descriptive and Anthropometric Data…….44 
 Secondary Descriptive Data for Covariates………...45 
Laboratory Methods 
 Human Milk Analysis………………………………46 
 Plasma and Red Blood Cell Total Phospholipid Fatty             
Acid Analysis………………………………………..47 
   Statistical Analysis…………………………………………48 
4. Results……………………………………………………………...52 
Prevalence of URIs………………………………………....53 
Prevalence of Dermatitis…………………………………....57 
Fatty Acid Composition of Plasma and RBC Total 
Phospholipids………………………………………………62 
Fatty Acid Composition of Human Milk…………………..63 
Influential Factors Affecting URI and Dermatitis 
Development……………………………………………….64 
5. Discussion 
Prevalence of Upper Respiratory Illness…………………...67 
vii 
 
Prevalence of Dermatitis…………………………………….69 
DHA Concentration and Early Illnesses…………………….71 
Confounding Variables……………………………………...73 
Limitations…………………………………………………..73 
Exploratory Data for Larger Study………………………….76 
6. Summary…………………………………………………………….79 
7. References.................................................................................81 
 
List of Tables 
 1. Properties of Immunoglobulins…………………………………………..12  
 2. Types and Functions of Cytokines in the Immune Response……………15  
 3. Summary Statistics of Study Population…………………………………53 
 4. Number of Infants with URI and Number of URI Episodes…………….57 
 5. Number of Infants with Dermatitis and Number of Dermatitis Episodes..61 
 6. Weight percent of AA and DHA Concentration………………………...62 
 7. Summary Statistics of Influential Factors for 16 Weeks……………….66 
 8. Summary Statistics of Influential Factors for 26 Weeks.....................66 
List of Figures 
 1. Frequency of URI Episodes……………………………………………..54 
 2. Age of First URI and Weeks Fed Human Milk…………………………55 
 3. Number of Dermatitis Episodes and Weeks Fed Human Milk………….58 
viii 
 
 4. Number of Dermatitis Episodes and Weeks Fed Human Milk to 6 Months 
     of age……………………………………………………………………59 
 5. Frequency of Dermatitis Episode in First 12 Months of Life………….61 
 6. Mean Relative DHA Exposure in Infancy………………………………64 
Appendices 
 A. Sample of Anthropometric Data Form…………………………….......91 
 B. Sample of Descriptive Data Form…………………………………......94 
 C. Human Milk Fatty Acids Analysis………………………………….....102 
 D. Plasma and Red Blood Cell Fatty Acid Analysis…………………......107 
 E. Tabulation for Number of URIs and Dermatitis Episodes Diagnosed in 3 
      month Intervals……………………………………………………......114 
 
 
 
 
 
 
 
 
 
ix 
 
GLOSSARY 
Allergen: antigen which produces an allergic response 
Antibodies: proteins produced by B-cells after stimulation by an antigen that act 
against the foreign substance in an immune response 
Antigen: any foreign substance that is bound by a specific antibody or lymphocytes 
Atopic Dermatitis: chronic inflammation of the skin that may be related to other 
atopic diseases 
Atopy: term used to describe an immunoglobulin E mediated allergic response 
B-lymphocytes: precursors of antibody-forming plasma cells 
Cytokines: substances secreted by cells that have effects on other cells 
Eczema: an inflammatory condition of the skin causing redness and itching and 
oozing lesions which become scaly and crusted 
Dermatitis: general term to describe inflammation of the skin 
Helper T-cells: subset of T-cells that stimulate B-cells (plasma cells) to make 
antibodies against thymus-dependent antigens 
Hypersensitivity: greater than normal immune response, same as allergy 
Immunoglobulin: term used for antibodies 
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Interleukins: glycoproteins secreted by leukocytes that have effects on other 
leukocytes 
Lymphocytes: cells in blood and tissues that contains antigen-specific receptors 
Lymphokines: substances secreted by lymphocytes 
Macrophages: phagocytic cell 
Phagocytosis: engulfment of a particle by leukocytes 
Upper Respiratory Illness: illnesses caused by an acute infection which involves the 
upper respiratory tract 
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CHAPTER 1: INTRODUCTION 
What is immunity? 
The immune system is a complex body system that begins to develop in utero 
and continues to mature throughout childhood (1). Immunity is important for 
protecting organisms from any foreign substances that attempt to invade. The immune 
system is composed of innate immunity (present at birth) and adapted or acquired 
immunity. Innate immunity is always present and available on short notice to protect 
against nonspecific foreign agents. Inflammation is part of the body’s immediate 
response and is part of innate immunity.  Acquired immunity is more specialized and 
develops after the body has already been exposed to a specific antigen. A normal 
immune response fights common illnesses and infections and they resolve after a 
period of time.  
Abnormal immune responses can occur as well and lead to autoimmune 
diseases, chronic inflammation, allergies and asthma. An allergy is a common 
example of an abnormal immune response. Allergy occurs when there is an 
overreaction of the immune response, which then becomes more problematic than 
protective. An imbalance of T-helper-1 (Th-1) cytokine production (interferon-
gamma and interleukin-2) and T-helper-2 (Th-2) cytokines (interleukin-4 and 
interleukin-5) may be the cause of certain allergies. Th-2 lymphocyte cytokines 
stimulate antibody production, especially immunoglobulin E, which is important in an 
allergic response. Normal and abnormal immune function is discussed in detail in 
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chapter 2. Immunity in utero, infancy and early childhood has also been examined. It 
is important to understand early childhood illnesses and their relationship to the 
development of chronic illnesses later in life.  
Upper Respiratory Illness, Dermatitis and Allergy   
The term “atopic march” has been used for some time to describe the 
progression of allergic manifestations in early childhood. Many times the first signs 
of allergic disease are atopic dermatitis and food allergy presenting within the first 
two years of life (2). Acute respiratory illnesses (ARI) and dermatitis are the most 
frequently diagnosed clinical pediatric illness (3-5).  ARIs and dermatitis occurring in 
an underdeveloped immune system in early infancy may increase the risk of 
developing asthma and allergy symptoms later in life (3, 5, 6).  According to Hahn et 
al. (2) , children with atopic dermatitis within the first two years of life were more 
likely to have wheezing during that same time than children without atopic dermatitis. 
As well, the children with atopic dermatitis and wheezing were at a threefold greater 
risk of wheezing at 7 years of age compared to children without an early onset of 
atopic dermatitis.  
The prevalence of allergic manifestations in infants is increasing worldwide 
(5).  Infants’ immune function is not fully mature at birth because acquired immunity 
develops with exposure to new antigens. Neonates’ immune function relies on 
antibodies (immunoglobulins), cells, cytokines and other proteins reviewed in this 
paper from their mothers during intrauterine life for protection.  Research now is 
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examining the relationship between the duration of breast feeding and infant immune 
function. It is known that maternal antibodies passed to the infant in utero and in 
human milk decrease in the first 6-12 months of life. Discovering ways to enhance 
maturation of the infant immune system is important in order to prevent illnesses in 
early childhood (4).   
Protective Factors of Human Milk 
Research has also examined the relationship of breast feeding compared to 
formula feeding in the development of illnesses early in life. Results of several 
studies suggest that breast-fed infants have a more mature immune system and fewer 
respiratory illnesses than formula-fed infants due to the immunoprotective factors in 
human milk (6-8).   
Secretory IgA is one such immunoprotective component of human milk that is 
passed to the infant and survives in the infant respiratory and GI tract. Secretory IgA 
may be one of the main sources of antibodies that protects against respiratory and 
gastrointestinal illnesses (4). Several studies have shown a relationship between 
human milk consumption and lower incidence of respiratory illness (7-10). Results 
from a study conducted by Chantry et al. (7) found that infants who were breast fed 
for greater than 6 months had a lower incidence of respiratory illness than infants who 
were exclusively formula fed or breast fed for less than 6 months.  Oddy et al. (8) also 
looked at infant feeding to determine if human milk for a longer duration was 
protective.  These researchers found a strong relationship between any breast feeding 
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and protection against respiratory morbidity in infants compared to no exposure to 
human milk.  Another study conducted by Sinha et al. (10) found that breast feeding 
was inversely associated with neonatal respiratory tract infections among female 
infants but not among male infants. The author speculated that the discrepancy 
between the genders was due to more heterogeneous respiratory conditions in male 
infants that were diagnosed as respiratory tract infections.  
In contrast, Kramer et al. (11) did not find exclusive breast feeding for greater 
than 6 months protective against asthma or allergic manifestations in infancy. 
However, based on the researchers’ methods, there was a lower degree of confidence 
in the results because they had to exclude 6 polyclinics for exceedingly high rates of 
positive skin pricks suggesting a systematic error.  The effect of human milk versus 
formula feeding on the maturation of the infant immune function deserves further 
study.   
Long Chain Polyunsaturated Fatty Acids (PUFAs) and the Infant Immune 
System 
More recently, research has focused on long chain polyunsaturated fatty acids 
(LCPUFAs) and their influence on immune function. Human milk contains both 
arachidonic acid (AA, 20:4n-6) and docosahexaenoic acid (DHA, 22:6n-3). AA and 
DHA were added to US infant formulas in 2002. AA synthesizes proinflammatory 
eicosanoids (prostaglandins, leukotrienes, and thromboxanes) that promote 
inflammation in an immune response. DHA has also been studied for potentially 
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positive immunomodulatory effects on the adult and infant immune system. Long-
chain n-3 PUFAs decrease the production of proinflammatory eicosanoids, cytokines 
and reactive oxygen species, making them potential anti-inflammatory agents (12).   
A study by Kew et al. (13) demonstrated that supplementation with 3 grams of DHA 
for 4 weeks in healthy adults could reduce the expression of an early marker of T-
lymphocyte activation (this is explained in more detail in chapter 2).  Damsgaard et 
al. (14) supplemented healthy 9-month-old infants with a teaspoonful of fish oil per 
day for 3 months and increased red blood cell (RBC) n-3 PUFAs and reduced n-6 
PUFAs. N-3 PUFA supplementation decreased interleukin-10 (IL-10) production, 
evidence of lower Th-2 cell response. In theory, a lower Th-2 response could 
decrease infant allergy and enhance maturation of the immune system.  
Fish oil contains DHA and eicosapentaenoic acid (EPA, 20:5n-3) and fish oil 
supplementation will increase milk DHA and EPA. Dunstan et al. (15) measured 
secretory immunoglobulin A (sIgA) concentration in milk of mothers who were 
breast feeding with and without a fish oil supplement and showed sIgA was positively 
associated with milk DHA (22:6n-3) (p= 0.046) and DPA (22:5n-3) (p= 0.003) and 
inversely associated with linoleic acid (p= 0.034). Soluble CD14 is a component of 
innate immunity and has been associated with protection against many diseases, 
including allergic diseases. This topic is discussed in detail in chapter 2. Breast milk 
levels of soluble CD14 (sCD14) were correlated with 22:5n-3, and IgA concentration 
was correlated with milk IL-10, IL-6, IL-13 and sCD14 concentration. Overall, the 
study provided evidence that an increase in n-3 concentration in human milk could 
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increase IgA and sCD14 concentrations in human milk. The high concentrations in 
milk can be passed to the infant and enhance the infant’s immune system.  
Minns, et al. (16) conducted a study in US toddlers that measured RBC DHA 
before and after consumption of a milk-based beverage for 60 days containing various 
amounts of DHA. A secondary measure involved the collection of adverse events. 
The results from the adverse events showed that in 82 children, a difference was 
detected in the number of incidences of URIs. The infants who consumed the 
beverage containing 130 mg of DHA for two months had a significantly lower 
incidence of respiratory events than the group who consumed the control beverage 
without DHA (17% vs 45%, respectively; p= 0.024). The results suggested that US 
toddlers could benefit from higher DHA intake.   
There has been limited research on the relationship between maternal milk 
fatty acid composition and the prevalence of URIs, dermatitis and allergic 
manifestations in infants. Duchen, et al. (17) conducted a study including 63 atopic 
and 57 non-atopic mothers and their infants. They observed clinical symptoms of 
allergic disease in 22 out of 63 (35%) children of atopic mothers and 22 out of 57 
(39%) non-atopic mothers. The concentration of linoleic acid (LA) in milk increased 
from transitional milk to mature milk in atopic mothers but not in non-atopic mothers. 
The non-atopic mothers already had a high concentration of LA in transitional milk. 
The total n-6 to n-3 ratio was higher in milk from mothers of atopic children than in 
those of non-atopic children. At 3 months postpartum, the total SIgA concentration 
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was lower in milk from atopic compared to non-atopic mothers. A high AA to EPA 
ratio in milk and serum was related to the development of allergic symptoms in these 
children by 18 months of age. Because milk fatty acids reflect dietary fatty acid 
intake, it would be easy to manipulate milk fatty acid composition and examine the 
development of allergy and asthma experimentally. 
   In another study conducted by Dunstan et al. (18), 83 atopic mothers were 
supplemented with 4 1-gram fish oil capsules per day  in order to examine the 
influence of supplemented n-3 PUFAs on allergic manifestations in their infants. All 
neonatal cytokines to all allergens were lower in the fish oil supplemented group than 
in the control group.  Infants of mothers given supplements had less severe atopic 
disease at one year of age than infants in the control group. 
To our knowledge, there have not been any studies comparing immune 
function in infants fed human milk and formula since DHA and AA were added to 
US infant formulas in 2002.  
Environmental Factors Affecting Infants’ Immune Function 
 It is important to take into account other factors associated with asthma and 
allergy in order to control for any effects of these potentially confounding variables.  
Among these factors, smoking during pregnancy, smoking in the child’s home, 
daycare attendance, multiple children in the home and furred pets in the home have 
been found to influence the development of URIs, dermatitis and allergic 
manifestations in infancy. The factors that seem to protect against the development of 
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URIs, dermatitis, allergy and asthma include multiple siblings in the home, daycare 
attendance and a household pet exposure since birth. Those factors believed to 
adversely influence the immune system include smoking during pregnancy, exposure 
to second-hand smoke and a maternal history of allergy and asthma.  
A study by Gern et al. (19) suggested that early exposure to furred pets in the 
home may protect against the development of allergic sensitization by increasing IL-
10 and IL-13 cytokine secretions. Hugg et al. (20) found that early exposure to dogs 
in the home protected against allergies, while exposure to cats in the home increased 
the risk of developing asthma in childhood. de Meer et al. (21) observed atopic 
sensitization less frequently in children who had attended a daycare facility or who 
had a household pet before 2 years of age (OR= 0.73, 95% CI; 0.55-0.98, OR= 0.78, 
95% CI; 0.61-0.99, respectively). Having an older sibling in the home was not 
associated with atopic symptoms nor was having more than one older sibling in the 
home (OR= 0.88, 95% CI; 0.70-1.11). Rothers et al. (22) found that daycare exposure 
by 3 months of age was associated with decreased IgE levels in the first year of life 
compared with no daycare exposure or daycare exposure after 3 months of age. Only 
children with atopic or asthmatic mothers had lower IgE when in daycare compared 
to no daycare.  
Justification for Further Investigation 
Significant gaps exist in the literature. Currently, there are limited and mixed 
results from studies of the relationship of fatty acid composition in human milk to the 
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prevalence of URIs, dermatitis and allergic manifestations in the first year of life. 
Therefore, it is important to further examine human milk compared to infant formula 
consumption in the protection against URIs, dermatitis and allergic manifestations. It 
is equally as important to examine the relationship between fatty acid composition of 
human milk and infant formula and the prevalence of URIs, dermatitis, allergy and 
asthma. As evidenced by the studies noted above, there may be potential benefits with 
exclusive breast feeding for a longer duration, DHA supplementation in the neonate, 
and DHA supplementation in pregnant and lactating women for the maturation of the 
infant immune system.  By enhancing our knowledge of different components 
affecting immune function, we may find new ways to protect infants from developing 
URIs, dermatitis, allergy or asthma, or to delay the onset decrease of these conditions.   
Statement of Purpose 
 The purpose of this study is to a) compare the prevalence of upper respiratory 
illness, dermatitis and manifestations of allergy and asthma in human milk-fed infants 
and formula-fed infants during the first year of life and b) to determine if the 1st year 
fatty acid intake of DHA from mother’s milk and formula is associated with lower 
prevalence of upper respiratory illness, dermatitis and allergic manifestations during 
the first year of life.   
 
 
 
10 
 
Research Questions 
 Primary Question: 
1.  Does longer duration human milk feeding result in a difference of upper 
respiratory illness, dermatitis and allergic manifestations in the first year 
of life? 
Secondary Question: 
1. Is there a relationship between docosahexeanoic acid (DHA) or 
arachidonic acid (AA) intake from maternal milk and formula and the 
prevalence of upper respiratory illness, dermatitis and allergic 
manifestations in the first year of life?  
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CHAPTER 2: REVIEW OF LITERATURE 
What is Immunity? 
 The immune system is a body system designed to protect the organism from 
all manner of foreign agents that can result in infection (microorganisms) or allergy 
(food, pet dander and hair, plant pollen, environmental chemicals, etc.) (1). The 
immune system includes both innate and acquired immunity and begins to develop in 
utero and continues to mature in early childhood into adulthood.  
Innate immunity is present at birth and responds to any nonspecific foreign 
agent that attempts to enter the body (1). The skin and mucous membranes are the 
first barriers that respond to foreign substances immediately upon entry.  When a 
foreign substance passes the first barriers of protection, it is engulfed by leukocytes in 
a process called phagocytosis. Lysosomes in the leukocytes release enzymes to 
destroy the foreign substance.   
The second line of defense is adaptive immunity also known as acquired 
immunity. Adaptive immunity differs from innate immunity in that it is highly 
specific to antigens (1).  Antigen specificity occurs only after a previous exposure to a 
particular substance. There are three major cell types required for acquired immunity: 
thymus or T-cells, bone marrow or B-cells, and macrophages. Aquired immunity has 
both a cellular (cell-mediated) and humoral (antibody-mediated) component. 
Humoral immunity (antibody-mediated) consists of B lymphocytes (plasma cells), 
which secrete antibodies specific to an antigen. Antibodies are made up of serum 
globulins, and activated globulins are called immunoglobulins (Ig). Table 1 indicates 
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the types and functions of specific immunoglobulins as well as their placental passage 
and presence in human milk.  
TABLE 1 Properties of Immunoglobulins 
Immunoglobulins and Immune Function 
Name 
Where 
present Function 
Placental 
Passage 
Present in 
milk 
Immunoglobulin 
G (IgG) 
Serum 1. Activates the 
complement system 
Yes yes 
  2. Neutralizes toxins   
  3. Immobilizes 
mobile bacteria 
  
    4. Neutralizes viruses     
Immunoglobulin 
A (IgA) 
tears, saliva, 
human milk, 
sweat 
1. Primary defense 
against local 
infections 
No yes 
   2. Prevents viruses 
from entering the 
host cell 
    
Immunoglobulin 
M (IgM) 
Serum 1. Activates the 
complement system 
No trace 
    2. Important provider 
of early 
immunological 
defense 
    
Immunoglobulin 
E  (IgE) 
Serum 1. Important in an 
allergy response 
No no 
    2. Releases 
histamine, heparin, 
leukotrienes when 
activated 
    
 
   T-lymphocytes are responsible for cell-mediated immunity and includes both 
helper T-cells and cytotoxic T-cells (1). Cell-mediated immunity involves signaling 
in response to cytokines. The helper T-cells include T-helper type 1 and T-helper type 
2 (Th-1 and Th-2) that produce different cytokines. Th-1 cells produce the cytokines 
interferon-gamma (IFN-γ) and tumor necrosis factor alpha (TNF-α). Th-1 plays a role 
13 
 
in the cellular immune system and maximizes macrophages killing ability of foreign 
substances. Th-2 cells are partnered with B-cells and play a role in the humoral 
immune function stimulating B-cell proliferation and increasing antibody production. 
Th-2 cells produce interleukin-4 (IL-4), interleukin-5 (IL-5), interleukin-6 (IL-6), 
interleukin-10 (IL-10) and interleukin-13 (IL-13).  Innate and acquired immunity may 
both involve an inflammatory response. 
 Helper T-cells (Th-cells) release lymphokines that activate B cells (plasma 
cells). The types and functions of lymphokines are listed in table 2. During an 
inflammatory response, lymphokines released by T-cells induce activation of 
monocytes and macrophages that contain lysosomes increasing the destruction of 
foreign organisms or cells.  
  In cell-mediated immunity, the foreign substance invading the body is broken 
down and appears on the surface of macrophages complexed with class II major 
histocompatibility complex (MHC) proteins (23). This protein complex then interacts 
with an antigen-specific receptor on a helper T-lymphocyte leading to production of 
interleukins: interleukin-1 (IL-1) by macrophages and interleukin-2 (IL-2) by 
lymphocytes. This causes the activation and proliferation of specific helper- T cells 
and the end result is a delayed hypersensitivity reaction to the antigen. 
In antibody-mediated immunity, the MHC protein complex binds to receptors 
on the Th cell, which produces IL-2, IL-4 and IL-5. The interleukin proteins then 
activate the B-cells capable of producing antibodies specific for the antigen. 
Activated B-cells proliferate to form plasma cells that secrete immunoglobulins 
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(antibodies). When bacterial polysaccharides can activate B-cells directly, only 
immunoglobulin M (IgM) is produced. Interleukins 4 and 5 are then able to produce 
IgG, IgA, and IgE antibodies. B-cells are important for recognizing the invading 
microorganism with the surface IgM. IgM antigen receptor can then activate B-cells 
to produce antibodies against the majority of molecules known. 
 CD4+ is a glycoprotein that plays a role in adhesion of T-cells and non-T-cells 
(1). It is encoded by the CD4 gene and expressed on the surface of T-cells during 
various stages of development in the thymus. CD4+ interacts with the MHC Class II 
molecule. CD4+ is also expressed by monocytes (24, 25) and is detectable in blood 
(24).  CD4+  T-cells are essential for both cell-mediated immunity and antibody-
mediated immunity (26). In cell-mediated immunity, CD4+ cells bind to an antigen 
presented by macrophages and the T-cells release lymphokines that attract other cells 
to the area as part of the inflammatory response (1). In antibody mediated immunity, 
the CD4+ cells bind to an antigen presented by B cells and produce clones of these B 
cells that secrete antibodies against the foreign substance.  CD14+, on the other hand, 
is part of the innate immune system and encoded by the CD14 gene.  It exists in two 
forms and is either attached to the membrane or found in the soluble form (sCD14) 
(25). The liver and monocytes secrete the soluble form of CD14 as does the 
mammary gland. One role of CD14 in human milk is to regulate beneficial microbial 
growth in the infant gut (27).  
 
 
15 
 
Table 2 Types and functions of cytokines in the immune response. 
Cytokines in the Immune Response 
Name Produced/Secreted By Function 
Interleukin-I (IL-1) monocytes and macrophages 1. Stimulates acute-phase protein 
synthesis 
  2. Promotes T-cell proliferation 
    3. Fever-producing substance 
Interleukin-2 (IL-2) CD4+ Th-1 cells 1. Required for growth of some T-
cells 
    2. Activates B-cells to secrete 
immunoglobulins 
Interleukin-3 (IL-3) Primarily by T-cells 1. Growth factor for hematopoietic 
stem cells and for mast cells 
Interleukin-4 (IL-4) CD4+ Th-2 cells 1. Growth factor for B-cells and 
some T-cells 
  2. Enhances expression of MHC 
class II molecules on B-cells 
    3. Promotes production of IgE and 
IgG1 
Interleukin-5 (IL-5) CD4+ Th-2 cells 1. Stimulates B-cell growth 
  2. Stimulates immunoglobulin 
secretion 
    3. Constitutes a growth and 
differentiation factor for 
eosinophils 
Interleukin-6 (IL-6) Many cells, including T-
cells 
1. Induces acute phase protein 
synthesis 
  2. Promotes T-cell activation 
  3. Promotes IL-2 production 
    4. Stimulates secretion of 
immunoglobulins by B-cells 
Interleukin-7 (IL-7) Fibroblasts, endothelial 
cells, some T-cells 
1. Growth factor for pre-B and 
pre-T cells 
Interleukin-8 (IL-8) many cells 1. Draws neutrophils and 
granulocytes into the area where 
its being secreted 
Interleukin-10 (IL-10) monocytes and some 
lymphocytes 
1. Effects in regulation of the 
immune system and inflammation 
  2. Down-regulates expression of 
Th-1 cytokines, MHC class II 
antigens 
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  3. Enhances B-cell proliferation 
and antibody production 
    4. Can inhibit synthesis of pro-
inflammatory cytokines 
Interleukin-12 (IL-12) Macrophages 1. Involved in differentiation of T-
cells into Th-1 cells 
  2. Stimulates growth and function 
of T-cells 
    3. Stimulates production of 
Interferon-gamma and tumor 
necrosis factor 
Interferon-gamma (IFN-γ) Activated CD4+ Th-1 cells 1. Acivates killer T-cells, natural 
killer cells, and macrophages 
    2. Induces expression of MHC 
class II molecules 
Tumor Necrosis Factor 
(TNF) 
TNFα- monocytes, TNF-β-
T-cells 
1. Activate many different cells 
    2. Cytotoxic to some tumor cells 
in vitro 
 
Abnormal Immune Responses: Allergy and Atopy 
Abnormal immune responses include hypersensitivity, an overreaction of the 
immune response to an antigen. Allergy is defined as hypersensitivity to an antigen in 
response to a first exposure while asthma is defined as a chronic lung disorder 
triggered by hyper-reactivity to stimuli such as allergens (28).  Atopy is defined as an 
allergy, most likely hereditary, that occurs upon exposure of an allergen and is 
characterized by symptoms such as hay fever, hives, and asthma.  Asthma and allergy 
can occur independently; however, atopy is often associated with asthma as 
evidenced by increasing prevalence of asthma and skin-testing reactivity in the 
United Kingdom and Australia (29).  
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Hypersensitivity reactions occur during an allergic reaction which is discussed 
in more detail later. It is generally understood that increased risk of developing 
allergy and allergic inflammation may occur in response to an exaggerated expression 
of Th-2 activity or failure of Th-1 or T-regulatory function (9, 30).  The inflammatory 
response becomes out of control in a hypersensitivity reaction and begins to damage 
tissues and organs. An allergic response is caused by the expression of Th-2 
lymphocytes. Th-2 lymphocytes release interleukins (as noted above) that result in the 
production of IgE which in turn stimulates inflammatory cells (31).  
There are different classes of hypersensitivity reactions (1). Type I 
hypersensitivity reactions are mediated by IgE antibodies and cause anaphylactic 
reactions. This occurs only minutes after exposure to an antigen. Because Th-2 cells 
produce IL-4 and IL-13, Th-2 cells play an important role in this type of 
hypersensitivity. Type 1 hypersensitivity is believed to underly food allergy, 
autoimmunity, and inflammatory bowel diseases.  Type IV hypersensitivity is a cell-
mediated immune reaction and is mediated by T-cells rather than antibodies. Local 
damage to the cell occurs when T-cells release lymphokines that cause accumulation 
and activation of macrophages resulting in chronic inflammation. This type of 
reaction is also called delayed hypersensitivity because it does not occur immediately 
after exposure to an antigen. Rather it may occur 1-2 days after exposure to an 
antigen.  
The mechanism of atopic allergy is the Type I hypersensitivity reaction, which 
involves Th-2 lymphocytes. Contact with an allergen results in processing by an 
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antigen presenting cell followed by presentation to Th-2 helper cells, which help B 
cells make IgE antibody. Production of IgE is protective when in response to stimuli 
such as parasitic worms. However, it may cause allergic rhinitis, eczema, hives or 
analphylaxis when production is in response to harmless airborne or ingested 
allergens. Only 10% of the general population develops clinical symptoms from these 
airborne pathogens such as plant pollens, mold spores, and animal dander.  
Allergists have experimented with treatment for asthma and allergic disease 
since the 12th century when a Jewish physician and philosopher, Maimonides, 
produced a remedy of Rhazes to “clear the lungs of moisture, ease respiration and 
eliminate the cough” (32). The relationship of the environment to asthma and 
allergies was inferred by Maimonides who noted: “the first thing to consider is the 
provision of fresh air…” The air is then illustrated as, “city air is stagnant, turbid, and 
thick, the natural result of its big buildings, narrow streets, the refuse of its 
inhabitants…The air should be kept dry at all times by sweet scents, fumigation and 
drying agents. The concern for clean air is the foremost rule in preserving the health 
of one’s body and soul…” 
Although the general link of some environmental conditions to asthma and 
allergic disease was made by the 12th century, it was left to modern scientists to 
define the specific environmental agents associated with allergic disease and asthma 
and the mechanisms of action described earlier. It is not known why the prevalence of 
allergic disease and asthma has increased dramatically in the last four decades (29). 
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As of 2003, nearly five million children in the United States and 155 million 
individuals worldwide were afflicted with asthma (6).  
Normal and Abnormal Immunity in Development 
As noted above, immunity begins to develop during gestation and continues to 
mature into childhood.  Neonates are first protected by their mothers’ IgG antibodies 
passed through the placenta and in human milk, but neonatal IgG antibodies decline 
by 3 to 6 months of age (1, 23, 33). Human milk sIgA is also immunoprotective for 
the duration of breast feeding. The fetus begins to synthesize IgM and IgA antibodies 
in the fifth month of gestation.  
Acute respiratory illnesses (ARI) are a leading cause of morbidity and 
mortality in infants and are the most frequently diagnosed clinical pediatric illness (3, 
30).  URIs can be chronic or acute and are now recognized as increasing the risk of 
allergy and atopy. Rhinoviruses (4) and respiratory syncytial virus (RSV) (6) are the 
two most common viruses that are detected in URIs during infancy and both appear to 
increase the risk of allergy and atopic diseases in infancy. The mean number of 
episodes of upper respiratory illnesses (URI) during infancy was 4.08 with a range of 
0 to 11 episodes (3). Furthermore, neonates have limited ability to produce 
interleukin-2 (IL-2) from Th-1 cells (34), increasing their vulnerability to developing 
allergy or atopy. 
 According to the Centers for Disease Control and Prevention (35), the 
prevalence of asthma in US children younger than 4 years of age increased from 5.8 
percent in 2002 to 6.5 percent in 2005. The first manifestation of the “atopic march” 
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leading to asthma and allergy typically occurs in infancy and early childhood (29-31, 
36, 37) as food allergies and atopic dermatitis (5). Otitis media and allergic rhino-
conjunctivitis are other clinical symptoms of early allergic disease (30).  
Because it is understood that the first allergic manifestations may begin early 
in life, the immune function of neonates has been studied in the hope of learning how 
the developing immune system is programmed for protection. As well, the factors that 
influence normal and abnormal development of the immune system can be elucidated.   
Relationship between Intrauterine Environment and Later Allergy or Atopy 
 The fetal intestinal tract is one route of exposure to allergens in the mother’s 
environment that end up in amniotic fluid and are swallowed.  Placental transfer of an 
allergen complexed with the immunoglobulin- G subclass antibodies has been 
identified as a second route of allergen exposure (31). Research in the last 12 years 
has shown that specific allergen-induced responses can occur as early as 22 weeks’ 
gestation (38). 
  IgG is the only antibody that moves across the placental barrier to provide 
protection for the fetus (4, 39, 40). IgG has four subclasses (1) : IgG1 constitutes 70%, 
IgG2 20% and IgG3 and IgG4 approximately 10% of total IgG. Subclasses IgG1 and 
IgG3 bind strongly to monocytes, while IgG3 functions in complement binding.  The 
complement system results in cell lysis if the antibody is bound to an antigen. There 
is a rapid increase in fetal IgG in the third or fourth month of pregnancy and IgG 
levels are found in the fetus until birth. Because the fetus is unable to synthesize 
immunoglobulins, the fetal IgG must be from the mother. The half-life of IgG is 23 
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days and maternal levels of IgG begin to be replaced by neonate IgG beginning 
around 3 or 4 months of age.  
IgG2 is the only subclass of IgG that does not pass through the placenta. Hay 
et al. found that concentrations of IgG2 in the fetus were low compared to 
concentration of IgG2 in maternal serum, which was several fold greater (39).   
There is evidence that maternal IgG may have a role in enhancing the fetal 
immune response to an allergen (31) and in protection against upper respiratory 
illnesses (41).  A study done in Germany by Stiller et al. (42) found that low cord 
blood concentrations of IgG and IgG1 to cat dander were associated with atopic 
symptoms in early childhood while high concentrations of IgG to cat dander and 
birch pollen were associated with less atopic disease in children in this cohort. A 
study done in Britain by Warner (33) showed a similar relationship between high 
concentrations of cord blood IgG antibodies to cat dander and the major allergen of 
birch pollen and less atopy in children during the first 8 years of life. 
As noted earlier, it is generally understood that increased risk of developing 
allergy and allergic inflammation may occur in response to an exaggerated expression 
of Th-2 activity or failure of Th-1 or T-regulatory function (9, 30). As well, it has 
been noted that neonates have limited ability to produce the Th-1 interleukin-2 (IL-2) 
and T-helper cells that are important in the response to an allergen (34). This could 
increase their vulnerability to allergy or atopy depending upon maturity of their 
immune system at the time of exposure.  
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Much like the upper respiratory distress response to an allergen, during RSV 
infection, monocytes and macrophages play a role in the acute inflammatory process 
by producing cytokines IL-12 and IL-10 (6). IL-12 induces T-cells to produce IFN-γ 
and IL-2. IL-10 down-regulates cytokine production and produces the “asthma-
inducing” immune response. RSV also produces an increased release of 
proinflammatory markers such as TNF-α, IL-1, IL-6, IL-8, platlet-activating factor, 
and prostaglandin E2. Many prostaglandins cause vasoconstriction of the bronchial 
tubes making it harder to breathe. Prostaglandins are also explained in greater detail 
later.   
  Grzela et al. (43) examined a cohort of 43 infants in order to analyze the 
relationship of Th-2 IL-4 expression on monocytes during the first year of life and the 
occurrence of allergy symptoms in neonates. After one year of observation, 10 of 29 
children that expressed an increased IL-4 concentration developed severe atopic 
dermatitis. In 8 of the 10 children who developed severe atopic dermatitis, the cord 
blood monocytes and Th-lymphocytes contained high concentrations of IL-4 
suggesting that increased concentrations of IL-4 may be related to atopic dermatitis. 
Moreover, 6 of the 10 children who had atopic dermatitis showed a significant 
decrease in IL-12 after one year of observation (p= 0.02). They found evidence that 
higher expression of IL-4 was associated with suppressed expression of IL-12. This 
study may suggest that Th-2 compared to Th-1 predominance even before birth is 
associated with allergic and atopic symptoms in childhood.   
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Research has concentrated primarily on environmental factors rather than 
genetic factors because of the dramatic increase in prevalence of allergy and asthma,  
however,  family history of atopy clearly plays a role in the development of allergy 
and asthma in children who are at increased risk from environmental exposures (30).  
Maternal atopy is associated with a higher risk of development of atopic disease in 
the offspring than is paternal atopy. It has been suggested that an atopic mother 
generates a more susceptible placental environment to allergens. Even though IgE 
antibodies do not cross the placental barrier, the fetus is still exposed to higher serum 
levels of IgE in atopic mothers versus non-atopic mothers because IgE in amniotic 
fluid resembles the mother’s IgE serum levels (44).  
Other protective molecules such as IgM are present at birth. IgM is found in 
the intestine and is the first immunoglobulin to be made by the fetus.  IgM is the first 
immunoglobulin to bind to an antigen and initiate the complement sequence. The 
complement sequence is a series of serum proteins involved in the mediation of 
immune reactions (1).   Mucosal IgA antibodies from the mother are needed for 
protection against foreign agents in the environment (4, 45). Secretory IgA is passed 
to the infant in human milk and can be found in the respiratory and gastrointestinal 
tract of human milk-fed infants, where it provides protection against microorganisms 
in the mother’s environment (4).  
Soluble and membrane CD14 monocytes may help program a healthy 
neonatal immune system, and reduce the Th-2 preference associated with IgE 
production and atopic disease (25). The hereditary factors for allergic manifestations 
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and asthma have been studied in relation to single nucleotide polymorphisms (SNPs) 
of CD14 (24, 27, 46, 47) and show lower concentrations in children with atopic 
family history.  Zdolsek et al. (47) examined a cohort of 76 children and found that 
children with a double atopic family history had lower soluble CD14 (sCD14) levels 
than children with no atopic family history at 3, 12, and 18 months, and at 7 years of 
age. Children with or without maternal history of atopic disease had similar sCD14 
levels at birth, 3, 6, and 12 months, but at 7 years of age sCD14 levels were lower in 
children with a maternal history of atopic disease than in children with non-atopic 
mothers.  
In human milk, sCD14 concentrations are approximately 10-fold higher than 
in maternal plasma, suggesting that milk sCD14 could be of sufficient quantity to 
program the developing immune system (24). Infant formulas do not provide sCD14. 
Protective Factors of Human Milk 
The role of human milk immunoglobulins in maturation of the neonatal 
immune function has been extensively studied (4, 7-11, 34, 37, 48-52). In addition to 
sCD14 just discussed, there are other molecules and chemicals that contribute to the 
immunomodulatory effects of human milk feeding, including leukocytes (B-
lymphocytes, macrophages, neutrophils, and T- lymphocytes), oligosaccharides, 
bifidus factor, lysozyme, lactoferrin, IFN-γ, nucleotides, and cytokines (49). Human 
milk feeding may also stimulate the development of the neonate’s immune system by 
achieving a beneficial T-helper 1 / T-helper 2 ratio earlier than in formula-fed infants 
(53).   
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Human milk also contains an anti-inflammatory cytokine interleukin-10 (IL-
10) and proinflammatory cytokines (IL-1- β, IL-6, IL-8, and TNF -α) in variable 
amounts (34). IL-10 decreases the Th-1 response and inhibits pro-inflammatory 
cytokine release. This is important because increased inflammatory response may 
result in reduced intake, illness, and gut damage.  
The results of several observational studies suggest that human milk protects 
infants in developing countries against URIs (54-56), but the relationship between 
human milk consumption and the prevalence of URIs, asthma, and atopic dermatitis 
still remains controversial (8-11, 37, 48). Because URIs and other illnesses are 
common among all infants, researchers have examined the duration of feeding human 
milk in relationship to the prevalence of respiratory illness.  
Oddy et al. (8) conducted a study in Australia examining the relationship 
between breast feeding and respiratory morbidity in infancy. The prospective study 
included 2,602 infants cared for in antenatal clinics in Perth, Australia. Parents were 
asked to complete a diary card recording feeding history and illnesses. The illnesses 
recorded were those that required a visit to the physician or hospital. At the end of the 
first year, parents completed a questionnaire and a trained child health nurse at the 
clinic assessed the children for growth and development. Responses from the 
questionnaire were then coded using ICD 9 codes for illnesses.  
Respiratory illness and infection included diagnosis of unspecified URIs, 
tonsillitis, otitis media, otitis media with effusion, and wheezing, while lower 
respiratory tract infections included wheezing associated with respiratory illness, 
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bronchiolitis, bronchospasm, or asthma. Non-wheezing lower respiratory infections 
included chest infection, pneumonia, whooping cough, chronic cough, or croup. As a 
check for reliability and validity of parental reporting of illnesses, the investigators 
compared 100 hospital medical records against the parents’ notes and found 
agreement in 99 out of 100 cases suggesting that parents’ records were highly 
reliable.   
 Feeding was coded as either predominantly breast feeding, meaning that 
human milk was given as well as water or water based fluids, or partial breast 
feeding. Partial breast feeding was described as other milk or formula had been given, 
but breast feeding had not yet stopped. The statistical analysis models adjusted for 
gender, gestational age, smoking in pregnancy, older siblings, maternal education, 
and maternal age at the time of birth. Other covariates considered but not found 
significant were birth weight, daycare attendance, father’s occupation, family income, 
concurrent parental smoking and parental history of asthma.  
 By 4 months of age, 48% of the cohort stopped predominant breast feeding or 
any breast feeding.  By 6 months of age, 61 percent of the mothers had stopped 
predominant breast feeding. By 8 months of age 58 percent had stopped breast 
feeding entirely. At 12 months of age 5 percent of the cohort was still breast feeding 
predominately, and 24 percent of the cohort were still partially breast feeding. Infants 
fed human milk for less than 2 months had 4 or more hospital and doctor visits 
because of a URI (p= 0.041). Those partially breast feeding for less than 6 months 
also had significantly more URIs (p= 0.018) compared to the rest of the cohort.  If 
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infants were weaned from breast feeding before 8 months of age they had an 
increased risk of 2 or more hospital, doctor, or clinic visits because of wheezing lower 
respiratory infections compared to those breast fed for greater than 8 months 
(p=0.001) (8).  Overall the results of the study provided evidence for benefits of 
longer duration breast feeding with regard to the number of hospital, doctor, and 
clinic visits for respiratory illnesses.  
Another study by Chantry et al.(7) looked at the relationship between duration 
of full breast feeding and respiratory tract infection in 2277 US children. Data for the 
study came from NHANES III and included 6 to 24-month-old children who had 
been breast fed in infancy. Breast-fed infants were categorized as fully breast fed less 
than one month, fully breast fed for one to four months, fully breast fed for four to six 
months, and fully breast fed for greater than or equal to six months.     
Pneumonia, colds or influenza, and wheezing were identified and recorded as 
respiratory tract infections. The number of episodes and age of first occurrence of 
otitis media were also recorded. Infants fully breast fed for greater than 6 months had 
less pneumonia than those fully breast fed for 4 to 6 months (p= 0.017).  The study 
also found that infants who were breast fed for only 1 to 3 months were more likely to 
have the first episode of otitis media before 1 year of age than those breast fed for 
longer (61.7 percent versus 47.2 percent, p= 0.016).  If full breast feeding stopped 
between 4 and 6 months of age, the risk of having greater than or equal to 3 episodes 
of otitis media was increased compared to full breast feeding for 6 months or longer. 
The results suggested that full breast feeding for greater than or equal to 6 months of 
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age provided greater protection against respiratory tract infection than did breast 
feeding for less than 6 months (7).  
Although the studies above are evidence that longer duration of breast feeding 
is protective against URIs, not all studies have found benefits of human milk versus 
formula feeding. Cushing et al.(51) examined the relationship between breast feeding 
and the risk of respiratory illness in 1,202 infants born in New Mexico between 1998 
and 1990. Parents recorded signs and symptoms of any illness displayed by the infant 
on a daily calendar. Symptoms included: runny nose, stuffy nose, fever, dry cough, 
wet cough, wheezing, difficulty breathing, loss of appetite, rash and the mother’s 
perception of illness. Even though the researchers had data until 18 months of age, the 
study focused on the first 6 months of the infant’s life when evidence has shown 
breast feeding to be most protective. Rates were expressed on an annualized basis 
reflecting 365 days at risk so that the rates could be compared across the breast 
feeding categories. The annualized rates for respiratory tract infections in infants 0 to 
2 months of age were 8.3 in infants who were not breast fed, 7.8 in infants who were 
partially breast fed, and 8.1 in infants who were fully breast fed. These numbers 
included upper and lower respiratory infections and did not demonstrate any benefit 
of human milk. It was noted that full breast feeding was associated with a shorter 
duration of all respiratory illnesses combined during the first 6 months of life (OR = 
0.90, CI; 0.83-0.98)  compared to partial human milk feeding and formula feeding. 
 A prospective study conducted in Copenhagen, Denmark by Rubin et al. (52) 
demonstrated a relationship between infant feeding and infectious illnesses during the 
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first year of life in a largely middle class population including 500 infants. 
Investigators collected demographic information and information about the plan for 
infant feeding in an interview conducted with mothers 3 to 4 days postpartum. 
Monthly mailed questionnaires obtained information about feeding, infectious 
illnesses, and covariates.  Inclusion criteria included: birth weight greater than 2,000 
grams, gestation greater than 36 weeks and absence of underlying diseases. After 
controlling for covariates, incidence density ratios were used to determine the 
prevalence of illness between breast fed and formula fed infants. The mothers did not 
have information about the hypothesis of the relationship between the type of feeding 
and illnesses or about the illnesses examined. 
The illnesses examined in the study were gastroenteritis, upper respiratory 
illness, otitis media, and lower respiratory illness. If not diagnosed by a physician, a 
diagnosis of upper respiratory infection required at least 2 of the following symptoms 
of the following criteria: a temperature greater than 38.5 ˚C, rhinorrhea, cough or fast 
breathing for 2 to 20 days. Three of the symptoms were required in cases where 
duration of symptoms was not known.  
Feeding was categorized according to the classification by the World Health 
Organization and included: 100 percent human milk-fed, human milk-fed greater than 
formula- fed, human milk-fed equal to formula-fed, human milk-fed less than 
formula-fed, and 100 percent formula-fed.  The ratio of incidence density was 
calculated in order to compare the rates of illnesses in the human milk-fed and 
formula-fed infants.  A ratio significantly greater than one meant that the rate among 
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formula-fed infants was higher than among those fed human milk, evidence that 
human milk-feeding was protective against infectious illness.  
After adjusting for birth weight, social class, number of children in the  
family, daycare and other illnesses in the family, breast feeding had a protective 
effect on otitis media but not against other common infectious diseases in infancy 
(52). The results were similar to those reported by Kramer et al. (11) and Cushing et 
al (51).  
Thirty-four atopic mothers and their infants were recruited at 35 to 36 weeks’ 
gestation for an infant follow up study conducted in Finland by Hoppu et al. (48). At 
the first study visit a questionnaire regarding family history of atopic disease was 
completed. The extent of maternal atopic sensitization was measured with skin prick 
tests for milk, egg, wheat, cod, soy bean, peanut, hazelnut, birch pollen, alder, 
mugwort, a mixture of six local grasses, cat, dog, house dust mite, and latex. 
Sensitization to three other foods was tested by a different technique. The diagnosis 
of atopic dermatitis was based on the Hanifin criteria, which requires the presence of 
3 of 4 major criteria and 3 of 23 minor cirteria established by experienced 
dermatologists. The infants of the mothers were then examined at 1, 3, 6 and 12 
months of age.  Four consecutive days of maternal food records were collected at the 
time the infant was one month old, and nutrient intakes were calculated using Nutrica 
software (version 3.0, Research Centre of Social Insurance Institution, Turku, 
Finland.)  If the mothers predominately or exclusively breast fed when the infant was 
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one month old, the fatty acid composition in the milk was analyzed by gas 
chromotography.  
By 12 months of age, 38 percent (13 of 34) of infants had been diagnosed with 
atopic dermatitis and of the 13 infants, seven had postive skin prick reactions to at 
least one of the allergens tested. Infants who developed atopic dermatitis had mothers 
with a significantly higher proportion of stearic acid in their milk compared to infants 
without atopic dermatitis (p= 0.0009) and the proportion of total n-3 PUFAs, 
specifically EPA, was lower in the milk of mothers whose infants developed atopic 
dermatitis than those whose infants did not develop atopic dermatitis. It is not clear 
how to interpret these results because differences, while statistically significant, were 
small, and there was a lot of overlap between the groups.  
Long Chain Polyunsaturated Fatty Acids (PUFAs) and the Infant Immune 
System 
Many PUFAs have been examined for their role in immune function including 
AA, linoleic acid, DPA and DHA. AA is a 20 carbon chain unsaturated at carbons 4, 
8, 11, and 14, and is oxygenated by cyclooxygenase to give prostaglandins and 
thromboxanes (1). Many prostaglandins and thromboxanes from AA are 
vasoconstrictive and can cause constriction of the bronchial tubes. Prostaglandins are 
also involved in immune regulation. Specifically, prostaglandin E2 synthesized from 
AA increases the production of IL-4, IL-5 and IL-10 (12). As noted before, IL-4 in 
turn stimulates IgE production and plays a role in allergy (57).   
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Calder (12) reviewed the relationship between long-chain n-3 fatty acids and 
the incidence of asthma. Eicosanoids derived from AA are produced by mast cells 
that mediate pulmonary inflammation in asthma. He cited two epidemiologic studies 
that linked asthma to a high intake of n-6 polyunsaturated fatty acids and a low intake 
of n-3 PUFAs (58, 59). However, a systematic review conducted on the relationship 
between fish oil supplementation and the prevalence of asthma symptoms conclude 
there was not a benefit of supplementation based on all available reports (12).  
 A study conducted by Kew et al.(13) sought to find effects of oils rich in EPA 
and DHA on immune cell composition and function. The researchers reported that 
fatty acid composition of plasma phospholipids was altered by supplementation of 
EPA and DHA, however, the effects of these two fatty acids on T-lymphocyte 
activation were different. The results suggested that supplementation with DHA, but 
not EPA, suppressed T-lymphocyte activation.  
Damsgaard  et al. (14) provided healthy 9–month-old infants for 3 months 
with a teaspoonful of fish oil and increased the n-3 PUFAs of their red blood cell, but 
did not affect any of the markers for inflammation measured. They did observe higher 
IFN-γ production and a tendency for lower IL-10 production compared to controls.   
Dunstan et al. (60) provided 83 atopic women at 20 weeks gestation with 4 
grams per day of fish oil capsules (n=40) (56% DHA and 27.7% EPA) or a placebo 
(n=43) and looked at neonatal allergen-specific immune responses in their infants. 
Although it did not reach statistical significance, the fish oil supplemented group had 
decreased IL-5, IL-13, IL-10, and IFN -γ responses to house dust mite, ovalbumin 
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(OVA), cat, and mitogen allergens compared to the group without fish oil 
supplementation.  The fish- oil supplemented group also had lower neonatal in vitro 
IL-10 response to cat allergen compared with the control group (p= 0.046). When the 
groups were analyzed using a linear-regression model, IL-5, IL-10, IL-13, and IFN-γ 
cytokine responses to allergens and mitogens were correlated inversely with PUFA 
composition of cord blood red blood cells.  As well, the control group was 3 times 
more likely to have a positive skin prick test to egg allergen compared to the fish oil 
supplemented group at one year of age (60). Both groups had similar amounts of 
dermatitis (p= 0.167), however, the fish-oil group were one-tenth as likely to have 
severe atopic dermatitis (OR= 0.09, 95% CI; 0.01-0.94) compared to the control 
group. The results suggested that fish oil supplemented during pregnancy could 
potentially reduce the severity of atopic disease in infants.  
A randomized, double-blinded, placebo-controlled clinical trial conducted by 
Krauss-Etschmann et al. (61) examined the effects of fish oil supplementation on 
altering the allergy-related immune parameters among mothers and their offspring. 
Beginning at 22 weeks gestation, 311 women were assigned to one of 4 groups: daily 
fish oil supplements containing either 0.5 grams of DHA and 0.15 grams of EPA, or 
400 micrograms of methyl-tetrahydrofolic acid, both supplements, or a placebo 
without either supplement.  
When compared to the placebo, fish oil supplementation was associated with 
increased maternal mRNA expression of IFN-γ and IL-1.  In cord blood samples, fish 
oil supplementation compared to the placebo was associated with decreased mRNA 
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levels of the Th-2- associated IL-13 and IL-4.  The results of the study are similar to 
those of Dunstan et al. (60) showing a decrease in IL-13 in offspring of mothers 
supplemented with n-3 PUFA, however the dose used was considerably lower. A 
follow up to this study may reveal if the decrease of Th-2 molecules decreases the 
incidence of allergic disease in offspring supplemented with fish oil.  
DHA and EPA Supplementation in Human Milk 
The evidence that n-3 fatty acid or a decrease in the ratio of n-6/n-3 fatty acids 
may play a role in maturation of the infant immune system provide the basis for 
examining the relationship of fatty acid composition of human milk and the infant 
immune system (48).  Human milk contains long chain n-3 PUFAs, predominately 
EPA and DHA (57).  Recent evidence suggests that DHA and AA, as well as 
conjugated linoleic acid in human milk may enhance the neonates’ immune function 
(48, 53).  DHA and EPA supplemented during gestation and lactation is passed to the 
infant in utero and in human milk altering cytokine production toward a more 
tolerable balance of Th-2/Th-1.  There have not been studies of the effects of fish oil 
supplementation on human milk immunoglobulins and therefore more research is 
needed to examine if there is a positive trend.  
 In 2004, Dunstan et al. (15) reported that fish oil supplementation during 
pregnancy increased the concentrations of DHA and EPA in RBC  (p<0.001) and 
decrease AA (p= 0.045) compared with the control group. IgA concentration were 
further positively associated with milk DHA (R= 0.235, p= 0.046) and DPA (22:5n-3) 
(R= 0.344, p= 0.003), and associated inversely with linoleic acid (R= -0.249, p= 
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0.034) in both groups. IgA concentrations were also positively correlated with levels 
of IL-10 (p< 0.001), IL-6 (p= 0.013), IL-13 (p= 0.001), and sCD14 (p= 0.004). The 
concentration of sCD14 in human milk was positively correlated with DPA (R= 
0.306, p= 0.009) in both groups. Despite the fact that there was no significant 
difference between the control group and the fish oil group in the concentration of 
any of the immunological parameters studied, higher n-3 PUFA levels correlated with 
higher levels of IgA and sCD14.  The results suggested that IgA levels in human milk 
could be increased by increasing the 22 carbon n-3 PUFA and decreasing the 20 
carbon n-6 PUFA concentrations. Higher IgA concentrations could have clinical 
benefits for the infant. 
 Duchen et al. (17) compared the composition of PUFAs and secretory IgA 
levels in mother’s milk of children allergic or not to different food proteins (Ova-
albumin and β-lactoglobulin) and an inhalant cat allergen. Blood samples were 
obtained from 120 children at birth and at 3 months of age. Skin prick tests were 
performed at 6, 12, and 18 months of age to assess allergic responses in the children. 
Maternal milk samples were collected at birth and monthly during the lactation period 
and PUFAs were measured by gas chromotography.  
 The researchers found that EPA, DPA (22:5n-3) and DHA concentrations 
were lower in milk from mothers of allergic children compared to mothers with non-
allergic children (p< 0.05).  At 3 months of age, total IgA antibodies were lower in 
the allergic mothers’ milk, however, IgA antibody levels against β-LG, OVA, and cat 
were similar in atopic and non-atopic mothers’ milk. The study results agree with 
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other reports that found lower levels of n-6 and n-3 LCPUFAs in plasma 
phospholipids and membranes of atopic persons compared with non-atopic persons. 
The study also confirmed results of a previous study by Yu G et al. (62) that 
concentration of linoleic acid and linolenic acid are lower in early transitional milk 
from atopic mothers compared to non-atopic mothers. 
Environmental Factors Affecting Infants Immune Function 
 Environmental exposure to various pathogens and life-style exposures have 
been linked to early URIs and may be related to increased allergy and asthma 
prevalence in childhood compared to the past. However, we could not find any 
evidence related to changing environmental exposures in the years when allergy and 
asthma have increased. As well, we now understand that environmental exposures 
begin in utero. Consequently there is much work to be done to understand exposures 
that might increase susceptability to URIs leading to allergy and asthma (29).   
Smoking during pregnancy, smoking in the child’s home, daycare attendance, the 
number of children in the home, and exposure to furred pets have all been shown to 
influence the development of URIs, allergy and asthma in early childhood (20, 21, 
63-65). 
   A study by Ball et al. (66) demonstrated that children who attended a daycare 
with many other children early in life had higher rates of URI in early childhood, but 
by age 8 these children were significantly less likely to have asthma than those 
children who did not attend a daycare or who did not attend a daycare with many 
other children.   
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Similar to that study, Rothers et al. (22) conducted a study to determine if the 
influence of early daycare exposure affected IgE levels in 434 children during the 
first 3 years of life.  Blood levels of IgE were obtained at 3 months, 1 year, 2 years, 
and 3 years of age. Information on daycare attendance was gathered monthly through 
4 months of age, and again at 6 and 9 months of age. The researchers found that total 
IgE levels increased with age (1.3 IU/mL at 3 months, 8.9 IU/mL at 12 months, 15.0 
IU/mL at 24 months, and 16.4 IU/mL at 36 months.)  Children attending daycare of 
any kind by 3 months of age were found to have marginally lower concentrations of 
IgE antibodies at each age compared to children who did not attend daycare (p= 0.007 
at 3 months, p= 0.004 at 1 year, p= 0.005 at 2 years, and p= 0.009 at 3 years). 
Maternal smoking either during pregnancy or postpartum, dogs or cats in the home 
and paternal atopy were unrelated to total IgE concentration in the cohort as a whole. 
By 3 years of age, daycare attendance outside the home without other children, and 
daycare attendance outside the home with other children were associated with lower 
IgE concentrations (p= 0.023 and p= 0.006, respectively) compared to children 
without daycare exposure. In relation to food allergen-specific IgE levels, the risk for 
having a food-allergy response was decreased through 3 years with any daycare 
exposure compared to without daycare exposure. However, lower IgE concentrations 
were not found for inhalant-specific IgE levels.  
 Between 1987 and 1994, Jaakkola et al. (65) investigated the relationship 
between maternal smoking in pregnancy and the risk of childhood asthma through the 
first 7 years of life in 58, 841 Finnish children. The investigators examined whether 
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childhood asthma was enhanced by reduced fetal growth due to smoking during 
pregnancy.  Maternal smoking during pregnancy was categorized as: nonsmoking, 
smoking less than 10 cigarettes per day, and smoking greater than 10 cigarettes per 
day. Asthma was defined as a child having at least one hospitalization due to asthma, 
at least one entitlement to free medication due to asthma or at least one entitlement to 
special care support due to asthma before 7 years of age. Adjustment was made for 
infant gender, birth order, low birth weight and pre-term delivery, and for maternal 
age, marital status and maternal occupation.   
 The investigators found that low birth weight and preterm delivery increased 
the risk of asthma (OR = 1.83, CI; 1.50-2.24, and OR = 1.64, CI; 1.38-1.95, 
respectively) compared to a normal birth weight and term delivery. The researchers 
also found that smoking during pregnancy increased the risk of asthma by 7 years of 
age (OR = 1.23, CI; 1.07- 1.42 for children of women who smoked less than 10 
cigarettes per day; OR 1.35, CI; 1.13-1.62 for children of women who smoked more 
than 10 cigarettes per day). After adjusting for fetal growth and preterm delivery, the 
effect of maternal smoking on asthma remained respectively: OR = 1.20, CI; 1.04-
1.38 and OR = 1.31, CI; 1.09-1.58.  Evidence that maternal smoking during 
pregnancy increases the risk of childhood asthma (65). 
 Other researchers have investigated the effects of second-hand smoke in 
relation to the development of allergy and asthma in young children (63, 67). A meta-
analysis of 53 studies reported between 1970 and 2005 examined exposure to second-
hand smoke and the development of childhood asthma (67). Researchers reviewed 53 
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studies, half case-controlled and half cross-sectional. Outcome search terms included 
asthma, wheezy bronchitis, asthmatic bronchitis, and reactive airway disease while 
exposure search terms included passive smoking, environmental tobacco smoke, 
second-hand smoke, and cigarette smoke.  
 Among the 53 studies, 200,000 children less than 18 years of age were 
examined. After controlling for family history of asthma and atopy, there was a 
positive association between household second-hand smoke exposure and the 
development of asthma. The meta-analysis found the relative risk to be 1.51 with a 
95% confidence interval of 1.31-1.75 (p= < 0.001) for household second-hand 
smoking after adjusting for covariates. The study suggested even in the absence of 
family history of atopy and asthma that second-hand smoke exposure increases the 
likelihood of developing asthma before 18 years of age.  
 With regard to risk of developing an allergic disease and asthma, early 
exposure to household pets has also been controversial. Pohlabeln et al. (68) 
examined 1,881 children during the first two years of life for development of allergy 
in relation to exposure to household pets. The mothers of these children completed 
the International Study of Asthma and Allergies in Childhood (ISAAC). Twenty-
three percent of the children showed symptoms of allergic disease with the majority 
being eczema (69.4 percent). Forty-one percent of the families with atopic children 
had household pets compared to 48 percent of the families without atopic children 
(p= 0.006). There was a non-significant trend towards less allergic symptoms in 
children without family history of asthma if they had a pet in the home since birth. In 
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children with a family history of allergic disease there was a trend toward an 
increased risk among those exposed to dogs since birth. Children without a family 
history of allergic disease had a lower risk of developing eczema and asthma in the 
first two years of life than children with a family history of allergy who were exposed 
to a dog in the home. The study suggested there is a protective factor of dog 
ownership in the development of atopic dermatitis and asthma in children.   
Zirngibl et al. (64) found a protective effect of dog ownership in a study of 4, 
578 children with and without a family history of allergic disease (OR= 0.63, 95% 
CI; 0.40-0.98). This study agreed with the hygiene hypothesis that early exposure to 
microbial substances is associated with decreased production of IgE antibodies, thus 
decreasing the risk for allergic disease (68). A recent study by Hugg et al. (20) also 
found that in 1, 106 children, exposure to dogs early in childhood reduced the risk of 
developing allergies and asthma (OR= 0.35, 95% CI; 0.13-0.95).  
 A variety of factors in the environment may influence the development of 
URIs, dermatitis and allergic manifestations. A family history of allergies and asthma 
increases the risk for offspring to develop allergies and asthma when exposed to an 
environmental allergen with adverse effects. The findings noted above provide 
guidance for protection against developing these chronic illnesses in infancy. Infants 
with a family history of allergies and asthma may gain added protection by pet 
exposure and attending daycare early in life. 
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CHAPTER 3: METHODS 
This is an exploratory study of a sample of convenience, of infants of women 
who participated in a double-blinded, randomized, controlled trial. The purpose of the 
study was to compare infant diet, including DHA intake to URIs, dermatitis and 
allergy in the first year of life. Data had been collected in the parent trial on feeding 
history, including food sources of DHA in the first year of life and maternal DHA 
status at entry into the study. The primary objective of the parent study was to 
determine if a dietary supplement of 600 mg/day of docosahexaenoic acid (DHA) 
during the last half of pregnancy would increase gestation duration and enhance the 
infants’ visual acuity, attention span and decrease distractibility in the first 18 months 
of life.  
Overview 
 Women between 8 and 20 weeks gestation were recruited from University of 
Kansas Medical Center and Truman Medical Center for the parent study. Each of 
these women received either 600 mg DHA in 3 capsules or a placebo in 3 capsules 
per day from enrollment to the birth of her baby.  Plasma and total RBC phospholipid 
fatty acid composition was collected at the time the women enrolled for the parent 
study and at delivery. Healthy infants born at term continued to be followed to 18 
months of age. Maternal milk samples were collected at the 6 week postpartum study 
visit from those mothers who were breast feeding at that time. Medical records of 
infants were obtained at one year of age. A 24-hour dietary recall and anthropometric 
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data were obtained at 6 weeks, 4 months, 6 months, 9 months, and 12 months of age. 
Other information regarding maternal allergies and asthma, smoking during 
pregnancy, smoking in the home, number of children in the home, daycare attendance 
and pet exposure were obtained at each of the follow up study visits until the infant 
reached 12 months of age. 
Setting 
 All study subjects reported to the University of Kansas Medical Center Infant 
Nutrition Clinic for parent-study appointments at 6 weeks, 4 months, 6 months, 9 
months, and at 12 months of age. Anthropometric data and descriptive data were 
collected at each of these 5 visits.  
Ethics 
 This study was approved by KU Medical Center Human Subjects Committee 
under the parent trial 1R01 HD047315 entitled Kansas University DHA Outcomes 
Study or KUDOS. The current study used data collected under that study to explore 
relationships of DHA intake and human milk intake in the first year of life on URIs, 
dermatitis and allergy development. These relationships were not planned as study 
outcomes; however, all data were collected for the purpose of including infant 
illnesses as part of adverse event monitoring.  
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Subject Selection 
 The mothers of subjects were recruited primarily through University of 
Kansas Medical Center and Truman Medical Center, as well as through flyers, 
brochures, my KUMC e-mail system and word of mouth.  The inclusion and 
exclusion criteria for the parent study included women between 8 and 20 weeks 
gestation, women who were 16 to 36 years of age, healthy women with a BMI less 
than 40 and a blood pressure less than 140/90 and women with no preexisting 
diabetes or medical conditions that would affect the outcome of their pregnancy. All 
subjects in the subordinate study met the following inclusion criteria: 
1. Offspring from mothers who consented in parent study and were assigned 
to 600 mg of DHA or placebo in the beginning of the second half of 
pregnancy, 
2. Infants healthy (without a congenital disease) and born at term (at least 37 
weeks gestation), 
3. Infants at least 12 months of age, 
4. Availability of a milk sample in mothers who breast fed for at least 6 
weeks postpartum of known DHA content, 
5. Available medical records through 12 months of age. 
 The first infant study visit was in July of 2006. Data collection for the 
subordinate study began in October 2008 and continued until February 2009. All 
primary descriptive, anthropometric, and dietary data as well as human milk samples 
44 
 
were collected between July 2006 and January 2009. Secondary descriptive data 
related to maternal allergies and asthma, smoking during pregnancy, smoking in the 
home, number of siblings in the home, daycare attendance and pet exposure was 
collected between the months of October 2008 and January 2009 after receiving 
permission from the HSC for an amendment to the approved protocol. 
Data Collection 
Anthropometric Data 
 At each study visit (6 weeks, 4 months, 6 months, 9 months and 12 months of 
age), body weight was obtained using a standard calibrated scale to the nearest gram, 
and body length was determined recumbent on a length board measuring to the 
nearest centimeter.  
Dietary Intake Data 
A 24-hour dietary recall was obtained at each study visit by registered 
dietitians trained in the Multiple Pass Methodology of interviewing. To determine 
breast feeding, the mother was asked to indicate time of breast feeding and any 
formula feeding. For formula-fed infants, questions were asked regarding when infant 
formulas were consumed and the amount and type of infant formula. By the end of 
the exploratory study, the 24-hour dietary recalls were more detailed and included the 
time of breast-feeding as well as how infant formula was prepared and how much of 
the infant formula the child actually consumed.  
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Medical Records 
Medical records through 12 months of age were obtained from the study 
subjects’ primary care physician as part of the parent study collection of adverse 
events. URIs and allergic manifestations documented in the infants’ medical records 
were recorded as URI, otitis media, croup, allergy and asthma. If 2 or more symptoms 
were noted for duration of at least 3 days, i.e. rhinorrhea, congestion and cough, these 
were recorded as one URI episode. Dermatitis was also recorded as atopic dermatitis, 
eczema and rash of unknown origin for duration greater than 3 days. 
Primary Descriptive and Anthropometric Data 
 Primary descriptive and anthropometric data were obtained from the delivery 
medical records and included the infant’s gender, race, birth length and birth weight 
as well as maternal cigarette and alcohol use during and prior to pregnancy 
(Appendix A). 
Descriptive Data Obtained for Covariate Analysis with Upper Respiratory Illness and 
Allergic Manifestation Status 
 The infants’ parent(s) or caregiver(s) answered questions at the 12 month 
parent-study follow up visit about factors believed to influence the development of 
URI, allergy and asthma. The questions included if the mother smoked during 
pregnancy, the number of people who smoked in the home, number of children under 
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the age of 13 in the home, maternal history of asthma and allergies, number and type 
of furred pets in the home and daycare attendance. (Appendix B).  
Laboratory Methods 
Human Milk Analysis 
 Lactating women were sent a sterile container which they returned at the 6 
week parent-study follow up visit with a milk sample. The sample was logged and 
kept frozen at -80ºC until analysis. Methanol containing BHT (4 mL) was added to 15 
mL extraction tubes containing 0.5 mL of human milk. Eight milliliters of chloroform 
was added and vortexed for 15 minutes. Next, 1.6 mL of 0.05M KCl was added and 
centrifuged for 5 minutes at 750 r.p.m. The upper phase was discarded, and the lower 
phase was evaporated in a 35ºC water bath. The sample was then transmethylated 
with 0.25 mL BF3 14% solution in methanol, 0.2 mL Benzene, and 0.55 mL 
methanol. After this was layered with N2, it was placed on ice until all samples were 
finished. The samples were then placed in a dry bath at 100 ºC for 30 minutes. Next, 
they were placed on ice and 1 mL of distilled H2O and 2 mL of pentane were added. 
Samples were vortexed in order to extract fatty acid methyl esters into the pentane 
phase and centrifuged for 5 minutes at 800 r.p.m. When the samples were completely 
dry under nitrogen dissolved in 10 µl dichloromethane, they were analyzed by gas 
chromatography using an autoanalyzer to determine the concentration of each fatty 
acid methyl ester or the weight (g/100g) of each fatty acid. (Appendix C.) 
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Plasma and Red Blood Cell Total Phospholipid Fatty Acid Analysis 
 For each woman, plasma and red blood cell total phospholipid fatty acid 
composition was analyzed at enrollment and at the time of delivery. Whole blood was 
collected in a sterile tube containing sodium heparin and centrifuged at 3000 g at 4ºC 
to separate plasma and red blood cells. Four mL of methanol and BHT were pipeted 
into sterile 15 mL extraction tubes. Five hundred microliters of blood or plasma was 
added and vortexed. Eight mL of chloroform was then added and vortexed; 15 
minutes for red blood cells and 10 minutes for plasma. The contents were then added 
to a clean extraction tube and 1.6 mL of 0.05M KCl was added and vortexed for 10 
seconds. This was then centrifuged for 5 minutes at 750 r.p.m. and the upper phase 
was discarded. The lower phase was evaporated in a 35ºC water bath under nitrogen. 
Total phospholipids were separated and identified using the Smuts et al. (69) 
technique. For transmethylation, each sample was layered with N2 and placed in a dry 
bath at 100ºC for 10 minutes. Once transmethylation was complete, samples were 
cooled on ice and 1mL of distilled H2O and 2 mL of pentane were added. The 
samples were then vortexed for 1-2 minutes in order to extract fatty acid methyl esters 
into the pentane phase and then centrifuged for 5 minutes at 800 r.p.m. Next, the 
samples were evaporated under nitrogen dissolved in 10 µl dichloromethane and 
analyzed by gas chromatography using an autoanalyzer.  (Appendix D).  
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Statistical Analysis 
Complete data were obtained for 50 infants. Forty-one of the 50 infants were 
fed human milk for some duration of time, consequently most of the analyses used 
duration of human milk feeding as the independent variable. There were 25 subjects 
fed human milk greater than 16 weeks and 25 subjects fed human milk for less than 
16 weeks, including 9 infants fed exclusively formula. Of the 50 original subjects, 
only 8 infants (16%) were exclusively fed human milk until at least 52 weeks of age. 
Most subjects (33 of 50, or 66%) were fed both human milk and infant formula for 
some duration of time in infancy.   
For some statistical analyses, subjects were evaluated using a continuous 
variable, i.e. weeks of human milk feeding, or by comparing those fed human milk 
for greater than 16 weeks compared to less than 16 weeks or greater than 26 weeks 
compared to less than 26 weeks. Greater than and less than 16 weeks and greater than 
or less than 26 weeks was used for statistical analyses based on previous evidence 
that human milk feeding is immunoprotective if fed for 4 to 6 months compared to 
less than 4 months. Those fed human milk for 16 weeks or more were recorded as 
receiving human milk for the exact number of weeks fed human milk up to 52 weeks 
of age because outcomes were not measured beyond 52 weeks.  
Descriptive Data, URIs and Dermatitis 
Means, standard deviations, and ranges were calculated for descriptive data 
for the 50 infants. The total number of URI and dermatitis episodes diagnosed for the 
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group fed human milk less than 16 weeks and greater than 16 weeks were recorded 
before 6 months of age and between 6 and 12 months of age. The total number of 
infants in each group who experienced a URI and/or dermatitis was recorded before 6 
months of age and between 6 and 12 months of age. The number of infants and total 
number of URI and dermatitis episodes between 0 and 3, 3 and 6, 6 and 10 and 10 
and 12 months are tabulated by duration of human milk feeding (greater than or less 
than 16 weeks) in Appendix E.   
The duration of human milk feeding in relation to respiratory illness and 
dermatitis was also evaluated up to 6 months (26 weeks) using an independent 
samples t-test. This was done in order to test if human milk feeding greater than 16 
weeks results in a statistically significant difference in relation to URIs and 
dermatitis.  The median for the age of the first diagnosed URI and first diagnosed 
dermatitis episode was measured for infants fed human milk less than or greater than 
16 weeks. Pearson’s Product Moment correlations were used for simple correlation 
analysis for descriptive data, number of weeks the infants were fed human milk and 
the number of URI and dermatitis episodes diagnosed, as well as the age of the first 
occurrence of an URI and/or dermatitis episode. 
DHA Concentration and Calculated Relative DHA Exposure 
The weight percent for plasma RBC total phospholipids for DHA and AA at 
enrollment were available for all 50 subjects. Weight percent for plasma RBC total 
phospholipids DHA and AA at delivery were available for 48 of the 50 original 
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subjects (96%).  Milk DHA and AA intake at 6 weeks lactation was available for 35 
infants; 25 of the 25 human milk-feeders (100%) and 10 of those fed human milk less 
than 16 weeks but greater than 6 weeks (40%) as they had milk samples available for 
the 6-week follow up visit.  Means, standard deviations and ranges were calculated 
for fatty acid composition data of the total RBC plasma phospholipids at enrollment 
and delivery, and human milk fatty acid composition for the groups fed human milk 
for greater than or less than 16 weeks.  
Because 66% of our subjects were “mixed” feeders (fed both formula and 
human milk for some duration of time), we attempted to calculate infant relative 
DHA exposure from formula and human milk by multiplying the number of weeks 
the infant was fed human milk by the weight percent of DHA samples. The number of 
weeks the infant consumed formula was multiplied by the DHA concentration in the 
infant formula that they received. If the infant received both milk and formula for 
some duration of time, the two DHA exposure concentrations were added together. 
We tested for statistical differences for the number of URI and dermatitis episodes 
diagnosed in the formula-fed group and the human milk-fed group with total DHA 
exposure in the first 6 months of life as well as for 0-12 months. Pearson’s Product 
Moment correlations were used to test whether or not there was a statistically 
significant difference in relative DHA exposure and the number of URI and 
dermatitis episodes diagnosed in either group.  
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Covariate Analysis 
  Covariates considered included if the mother smoked during pregnancy, 
smoking in the home, maternal allergies and asthma, pet exposure, daycare 
attendance and number of children in the home under the age of 13. However, only 
one was related to URIs or dermatitis for either group. As well, an independent 
samples t-test was also used to test differences in the covariates with duration of less 
than or greater than 26 weeks.   
All statistical procedures were done using Microsoft Office Excel 2007® for 
Windows (Microsoft Corp., Seattle, WA) and SPSS® version 16.0 (SPSS Inc., 
Chicago, IL). Significance was determined by alpha less than 0.05 and all p-values 
were based on two-sided tests.  
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CHAPTER 4: RESULTS 
 The objective of this study was to a) determine the relationship between 
duration of human milk feeding and the prevalence of URI, dermatitis, allergies and 
asthma in the first year of life and b) to determine if there is a relationship between 
fatty acid composition, particularly DHA, in maternal milk and in infant formula and 
the prevalence of URI, dermatitis, asthma and allergies.  
All available subjects (n=50) were used to generate summary statistics (Table 
3). For the two groups of infants defined by milk feeding (breast feeding greater than 
or less than 16 weeks), gestational age, birth weight, birth length, head circumference 
and duration of human milk feeding were obtained from the parent study. Nine of the 
50 original subjects (18%) were fed only formula for 52 or more weeks. Eight of the 
50 original subjects (16%) were fed only human milk for 52 or more weeks. The 
remaining 33 subjects (66%) were fed human milk and infant formula for some 
duration of time.  The formula-fed group (n=25) included infants who were fed 
exclusively or predominately formula and were fed human milk for less than 16 
weeks. The human milk-fed group (n=25) included infants who were fed exclusively 
or predominately human milk for greater than 16 weeks, although they may have also 
received formula for some duration of time.  
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TABLE 3 Summary statistics of study population 
  Formula-Fed Breast-Fed  
(n=25) (n=25) 
Characteristic 
Gender 
       Male 14 9 
       Female 11 16 
Gestational Age (wks) 
      Mean ± SD 39.2 ± 1.3 39.9 ± 0.8 
      Range 37-41.2 38.4-41.3 
Birth Weight (g) 
      Mean ± SD 3306 ± 429.9 3523 ± 486.2 
      Range 2043-4075 2615-4190 
Birth Length (cm) 
      Mean ± SD 50.1 ± 1.5 50.3 ± 2.4 
      Range 43.2-53.8 47-55.8 
Head Circumference (cm) 
      Mean ± SD 34.1 ± 1.5 34.6 ± 1.4 
      Range 29-36 32-37.5 
Duration of Human Milk Feeding 
(wks) 
      Mean ± SD 5.6 ± 5.7 44.8 ± 14.6 
      Range 0-15.9 17.6-52.0 
 
There were no differences in birth weight, length and head circumference or 
gestational age between the two defined feeding groups.  
Prevalence of URI  
In the sample as a whole, 39 of 50 infants (78%) experienced at least one URI 
in the first 12 months of life. Of the 11 infants who did not experience a URI in the 
first 12 months of life, 5 of those infants (45%) were in the formula-fed group (fed 
human milk less than 16 weeks) and 6 of those 11 infants (54%) were in the human 
 milk-fed group. Of the 39 infants who experienced a URI in the first 12 months of 
life, 17 (43%) experienced 1 URI, 11 (28%) experienced 2 URIs, 7 (18%) 
experienced 3 URIs, 2 (5%) experienced 4 URIs, 1 experienced 5 URIs (3%), and 1 
infant (3%) experienced 6 URIs.  Figure 1 shows the frequency of URIs experienced 
in the first 12 months of life in 
FIGURE 1 Frequency of URI for 39 of 50 infants who experienced a URI in the first 
12 months of life.  
Of the 50 infants, t
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weeks experienced their first URI approximately 7 weeks later compared to infants 
fed human milk less than 16 weeks. The median age for the first diagnosed URI of 
the 25 infants in the human milk-fed group was 26.71 weeks of age while the median 
age for the 25 infants fed human milk less than 16 weeks was 20.0 weeks. Figure 2 
shows the relationship between the age of the first diagnosed URI and the duration of 
human milk feeding in the first 12 months of life. 
 
FIGURE 2 Age of first URI compared to weeks fed human milk in the 39 infants 
who experienced a URI in the first 12 months of life.  
Fourteen of 25 (56%) infants fed human milk less than 16 weeks were 
diagnosed with at least one URI before 6 months of age with the total number of URI 
episodes before 6 months of age being 18. Thirteen of 25 (52%) infants fed human 
milk less than 16 weeks experienced at least one URI between 6 and 12 months of 
age with a total of 19 URI episodes in this group between 6 and 12 months of age. Six 
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of the 13 (46%) infants who experienced a URI between 6 and 12 months of age, did 
not experience a URI before 6 months of age.  
In the group of infants fed human milk greater than 16 weeks, 12 of 25 (48%) 
infants were diagnosed with a URI before 6 months of age and there were a total of 
20 URI episodes experienced in this group before 6 months of age. Between 6 and 12 
months of age, 15 of 25 human milk-fed infants (60%) were diagnosed with a URI 
and there were a total of 22 URI episodes between 6 and 12 months of age.  Seven of 
these 15 (47%) infants were not diagnosed with a URI before 6 months of age. A 
positive trend was found in infants fed human milk for at least 26 weeks compared to 
human milk-fed for 16 weeks for fewer URI episodes (p=0.519, p=0.767). Table 4 
shows the number of infants and number of URI episodes in each group before 6 
months of age and between 6 and 12 months of age. The age of the first diagnosed 
URI was unrelated to the diagnosis of allergy or asthma in the first year of life (p= 
0.740, p= 0.888, respectively). Similarly, the number of URIs before 6 months of age 
was unrelated to the diagnosis of allergy and asthma (p= 0.745, p= 0.419, 
respectively), as was the number of URIs between 6 and 12 months of age (p= 0.321, 
p= 0.175 respectively).  Appendix E shows the tabulation of URI episodes by 3 
month intervals (0-3 months, 3-6, 6-10, and 10-12 months).  
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TABLE 4 Number of Infants with URI and number of URI episodes 
  Formula Fed Human Milk  
  (n=25) (n=25) 
Mean Duration of Human Milk 
(wks) 
(n=25) 5.6 45.07 
Infants with URI before 6 months 14 12 
Number of URI Episodes before 6 
months 18 20 
Infants with URI 6-12 Months of 
Age 13 15 
Number of URI Episodes  6-12 
Months 19 22 
 
Prevalence of Dermatitis 
Dermatitis occurred in 11 of 25 (44%) human milk-fed infants and in 15 of 25 
(60%) formula-fed infants. A statistically significant inverse correlation was found 
for longer duration of human milk feeding and number of dermatitis episodes before 
6 months of age (R= -0.289, p= 0.044). This is shown in Figure 3. Based on this R, 
8.3% of the dermatitis episodes before 6 months of age can be explained by shorter 
duration of human milk feeding. Infants fed human milk for at least 26 weeks 
exhibited an even greater significant reduction in dermatitis episodes (R= -0.329, p= 
0.020) with an alpha = 0.05. Figure 4 shows the number of dermatitis episodes in 
relation to the weeks fed human milk before 6 months of age.   
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FIGURE 3 Number of dermatitis episodes and weeks fed human milk to 52 weeks of 
age (R=-0.289, p= 0.044).  
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FIGURE 4 Number of dermatitis episodes and weeks fed human milk to 6 months of 
age (26 weeks) (R = -0.329; p = 0.020). 
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experienced 2 dermatitis episodes. Table 5 shows the number of infants who 
experienced a dermatitis episode and the number of dermatitis episodes that occurred 
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in each group by 6 month intervals. Figure 5 shows the frequency of dermatitis 
episodes in the first 12 months of life in the two groups.  
Of the 25 infants fed human milk longer than 16 weeks, the median age for 
the first dermatitis was greater than 52 weeks with a range from 4.43 to greater than 
52 weeks of age.  The median age for the first diagnosed dermatitis episode was 
32.28 weeks with a range from 1.43 to greater than 52 weeks of age.  The age of the 
first diagnosed episode of dermatitis did not show a statistically significant 
correlation with the diagnosis of allergy or asthma in either group (p= 0.230, p= 
0.984, respectively).  The number of dermatitis episodes before 6 months of age did 
not statistically correlate with the diagnosis of allergy and asthma in either group (p= 
0.184, p= 0.185, respectively). The number of dermatitis episodes diagnosed between 
6 and 12 months of age and the diagnosis of allergy and asthma in the infant also 
were not statistically significant (p= 0.562, p= 0.216, respectively).  
  
FIGURE 5 Frequency of Dermatitis Episodes in the first 12 months of life in 26 of 
the 50 original subjects. 
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Fatty Acid Composition of RBC 
 The weight percent of plasma and red blood cell (RBC) total phospholipid 
fatty acid composition for AA and DHA at enrollment was available for all 50 
subjects. The weight percent for plasma and RBC total phospholipid fatty acid 
composition for AA and DHA at delivery was available for 48 of the 50 subjects 
(96%). Data were missing for the weight percent AA and DHA concentrations at 
delivery from one mother in the human milk-fed group and one mother in the 
formula-fed group. When the groups of mothers were measured as a whole, the mean 
weight percent AA concentration at enrollment was 15.65 with a range of 8.20-23.90. 
The mean weight percent AA concentration at delivery was 12.93 with a range of 
2.58-19.06. The mean weight percent DHA concentration at enrollment was 4.59 with 
a range of 1.73 to 8.60. The mean corrected weight percent DHA concentration at 
delivery was 5.92 with a range of 1.48 to 10.61. The AA and DHA fatty acid 
composition separated in to the two groups is displayed in Table 6. 
TABLE 6 Weight percent AA and DHA Concentration 
  Human Milk-Fed Formula-Fed 
  Enrollment Delivery Enrollment  Delivery 
  (n=25) (n=24) (n=25) (n=24) 
DHA (%)   
      Mean 5.05 6.7 4.12 5.14 
      Range 2.82-8.6 3.02-10.61 1.73-7.01 1.48-8.30 
     SD 1.48 2.42 1.4 1.7 
AA (%)   
      Mean 16.05 12.31 15.25 13.53 
      Range 11.02-23.9 8.18-15.9 8.19-20.42 2.58-19.06 
     SD 2.76 1.86 2.53 3.25 
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 No statistically significant differences were found in the total phospholipid 
weight percent of DHA or AA in mother’s who fed their infants human milk for 
greater than 16 weeks compared to mothers who fed their infants human milk less 
than 16 weeks.  
Fatty Acid Composition of Human Milk 
The fatty acid composition for human milk was available for 35 of the 50 
(70%) sub-study subjects at 6-weeks postpartum. The mean weight percent DHA 
concentration in the human milk was 0.28 and the mean weight percent for AA in 
human milk was 0.52. The mean relative DHA exposure for the amount of human 
milk and infant formula intake before 6 months of age for the group fed human milk 
less than 16 weeks was 7.6 with a range of 3.6 to 10.86 and for 12 months in the 
infants fed human milk less than 16 weeks was 14.8 with a range from 7.8 to 17.5.  
The mean relative DHA exposure before 6 months of age for the group of infants fed 
human milk greater than 16 weeks was 9.26 with a range of 3.2 to 21.8 and for 12 
months the mean relative DHA was 20.3 with a range from 11.6 to 48.  DHA 
exposure did not correlate with the number of URIs or dermatitis episodes, the age of 
the first URI or first dermatitis episode for either group or by interval of infancy 
(before 6 months of age or between 6 and 12 months of age).  Figure 6 shows the 
total relative first year DHA exposure by group.  
 FIGURE 6 Mean relative DHA exposure in infancy
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maternal history of asthma. The absence of a statistical difference does not mean that 
these groups are similar in regard to several risk factors like maternal history of 
asthma. In one case, a statistically significant inverse correlation was found between 
the number of weeks of human milk feeding and exposure to smoking in the home   
(R = -0.281, p= 0.048).   
When the data for influential factors in relation to human milk-feeding for 
greater than or less than 26 weeks was analyzed, significant trends were found with 
diagnosis of maternal asthma (p=0.041) and smoke exposure in the home (p= 0.009). 
Three women who breast fed their infants to 16 weeks did not feed human milk up to 
26 weeks. Two of these women were atopic and smoked during pregnancy, one of the 
women had asthma, and all three of the women’s infants were exposed to smoke in 
the home. Table 8 shows summary statistics for influential factors when comparing 
infants fed human milk for greater than 26 weeks compared to infants fed human milk 
for less than 26 weeks.   
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TABLE 7 Summary statistics of influential factors for human milk-fed greater than 
or less than 16 weeks 
  
Human milk-fed < 16 
weeks 
Human milk-fed > 16 
weeks 
Characteristic                    (n=25)                (n=25) 
Smoking During 
Pregnancy 8 (32%) 5 (20%) 
Smoking in the Home 6 (24%) 4 (16%) 
Other Children in the 
Home 16 (64%) 10 (40%) 
Daycare Attendance 11 (44%) 11 (44%) 
Furred Pets in the Home 9 (36%) 11 (44%) 
Atopic Mothers 12 (48%) 15 (60%) 
Maternal History of 
Asthma 8 (32%) 3 (12%) 
 
TABLE 8 Summary Statistics of influential factors for human milk-fed greater than 
or less than 26 weeks.  
  
Human milk-fed < 26 
weeks 
Human milk-fed > 26 
weeks 
Characteristic (n=22) (n=28) 
Smoking During Pregnancy 10 (45%) 3 (11%) 
Smoking in the Home 9 (41%) 1 (4%) ** 
Other Children in the Home 16 (73%) 10 (36%) 
Daycare Attendance 13 (59%) 9 (32%) 
Furred Pets in the Home 11 (50%) 9 (32%) 
Atopic Mothers 14 (64%) 13 (46%) 
Maternal History of Asthma 9 (41%) 2 (7%)* 
*P<0.05; **P<0.01 
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CHAPTER 5: DISCUSSION 
  URIs, atopic dermatitis, allergy and asthma are frequent clinical pediatric 
diagnoses. Finding a way to protect infants early in life from these illnesses is 
important for their immune function maturation, which is related to the “atopic 
march.”  Immunoprotective agents in human milk and the development of these 
illnesses have been extensively studied with mixed results (7-11). It has been argued 
that longer duration of human milk feeding may lead to decreased risk or delayed 
occurence of developing URIs (7, 8), dermatitis (48, 50), allergy and asthma (4, 50, 
70).  More recently, the relationships between fatty acid composition in human milk 
and the prevalence of URIs, dermatitis, allergy and asthma have been explored (14, 
18, 59, 60). 
Prevalence of Upper Respiratory Illnesses  
The total number of infants in our study who experienced at least one URI 
episode in the first 12 months of life (39 out of 50 or 78%) is consistent with previous 
findings (7, 8). As well, Sinha et al. (10) found a gender difference in infants who 
experienced URIs before 12 months of age with male infants having a greater number 
of URIs compared to female infants. Sinha et al. did not find a significant difference 
in the prevalence of URIs in the first 12 months of life in infants fed human milk less 
than 16 weeks compared to infants fed human milk greater than 16 weeks. Our data is 
in agreement with this finding. We did find a later onset of first URI among infants 
who consumed human milk for greater than 16 weeks compared to infants who 
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consumed human milk for less than 16 weeks (26.71 weeks vs. 20 weeks of age). 
This could be clinically significant in that a later onset of an illness may indicate a 
more mature immune system and/or later illness may protect against or slow the 
atopic march later in childhood.   
It is important to keep in mind that this is an exploratory evaluation and that it 
will eventually be applied to a sample of approximately 200 children. Non-significant 
trends would be hypothesized to be statistically significant at the completion of the 
study.  As well, we will be able to include the amount of DHA provided in utero as a 
covariate in the mixed model analysis for relationships between DHA exposure and 
illnesses in infancy and beyond as these children will be followed until 5 years of age. 
Accordingly, we should be able to evaluate the effects of human milk and DHA on 
both early and late illnesses.  
We examined the number of URI episodes diagnosed before 6 months of age 
and the number of URI episodes diagnosed between 6 and 12 months of age in infants 
fed human milk greater and less than 16 weeks and did not find any statistically 
significant differences. This could be for several reasons. Many infants (78% in our 
study) experience a runny nose, congestion or a cough before 12 months of age as we 
have discovered, but we do not know if all parent(s) or caregiver(s) took their child to 
their primary physician if they considered the illness minor or if the duration of the 
illness was short. Because only physician-diagnosed medical records were used in our 
study, there may have been more infants in either group who experienced a URI but 
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did not see a doctor. On the other hand, we are not sure this is a true limitation of the 
study as parent(s) or caregiver(s) were asked about recent illnesses at each visit and 
the study coordinator thought these reports correlated well (100%) with the medical 
records.  
Another reason for not detecting a difference in the number of URIs in the 
infants fed human milk greater than 16 weeks and those fed human milk less than 16 
weeks may be due to our small sample size with only approximately 25% of our 
study completed. Although we had an equal number of infants who were fed human 
milk less than 16 weeks and who were fed human milk greater than 16 weeks, a 
larger sample size may detect a difference in the number of infants who experienced a 
URI as well as the number of URI episodes diagnosed in each group. Statistically 
speaking, with an alpha set at 0.05 and a power of 0.80, 146 subjects per group would 
be needed to detect a decrease in the number of URI episodes by a half in the first 
year of life.  
Prevalence of Dermatitis 
 We found significantly fewer infants diagnosed with dermatitis before 6 
months of age in the group of infants fed human milk less than 16 weeks compared 
with the infants fed human milk greater than 16 weeks. This finding is consistent with 
previous findings in that human milk has immunoprotective factors against 
developing dermatitis early in life (2, 50, 54, 70). This finding is important to 
continue exploring with a larger sample size in order to determine if longer duration 
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of human milk feeding eventually protects against the atopic dermatitis link in the 
“atopic march.”   
 Our finding that longer duration of human milk feeding appears to protect 
against the development of atopic dermatitis in the first year of life agrees with 
Saaeinen et al. (71). The investigators found that human milk feeding for greater than 
6 months resulted in lowest prevalence of eczema at one and 3 years of age and 
slightly lower rates of atopy at 17 years of age compared to human milk feeding less 
than 6 months. These researchers also found the prevalence of eczema peaked at one 
year of age. Their results suggest that a short duration of human milk feeding does not 
protect against eczema compared to a longer duration of human milk feeding. We 
found that duration of human milk feeding was related to lower numbers of dermatitis 
episodes in infancy. 
 Although it did not reach statistical significance, the onset of the first 
dermatitis episode was later in the infants fed human milk greater than 16 weeks 
compared to those infants fed human milk less than 16 weeks (greater than 52 weeks 
versus 32.28 weeks). Our results suggest that duration of human milk feeding reduces 
dermatitis episodes before 6 months of age and delays appearances of dermatitis. This 
outcome is clinically important as studies have suggested earlier incidences of atopic 
dermatitis put the infant at a greater risk for developing allergy or asthma in 
childhood (6, 41). For example, Gustafsson et al. (72) found that onset of eczema 
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before 4 months of age was a significant risk factor for inhalant allergens at 36 
months or later (OR = 3.0, 95% CI; 1.0-8.6).  
DHA Concentration and Early Illnesses 
 Several recent studies have examined the relationship between DHA and 
immune function including the prevalence of URIs, dermatitis, allergy and asthma. 
Results are mixed. While we did not find a relationship to DHA exposure, it is 
important to keep in mind that all infants received DHA throughout infancy whether 
from human milk or formula. However, most infant formulas did not contain DHA 
only a few years back. If an infant in our study was fed human milk along with infant 
formula for some duration of time, this would further increase the amount of DHA 
consumed.  
We found that the mean DHA concentration in human milk (0.28 %) was 
similar to the DHA concentration found in the majority of infant formulas (0.35%). 
However, higher milk DHA is likely related to maternal DHA intake particularly as 
half of the women in each group would be expected to have received a DHA 
supplement during pregnancy. Accordingly, in utero and postnatal exposure to DHA 
in this subset of the parent study was highly variable.  Although not statistically 
significant, the mean corrected weight percent DHA concentration for the milk 
samples we analyzed was 0.07 less than what is found in some infant formulas.   
 The DHA exposure before 6 months of age and for 0 to 12 months of age was 
greater for infants fed human milk greater than 16 weeks compared to those fed 
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human milk less than 16 weeks. This was the case despite the fact that the DHA 
concentration in most infant formulas consumed was higher than the mean DHA 
concentration in human milk from the mothers in our study. Again this apparent 
difference could have been due to small sample size and outliers in the groups.  One 
mother in our study who breast fed her infant for greater than 16 weeks had a very 
high DHA concentration in her milk (0.76%), then also fed her child infant formula 
for the same duration of time as the human milk. Consequently, this infant had a 
much higher DHA exposure than the other infants in our study. On the other hand, 
one infant who received no human milk and was fed a lower DHA infant formula 
than most other infant formulas for the whole 52 weeks (Similac Advance®) had a 
lower DHA concentration exposure than most of the other infants in our study.   
 No significant differences were found in the weight percent DHA 
concentration and the number infants who experienced a URI. As well, no significant 
differences were found with DHA concentration and the number of URIs diagnosed 
before 6 months and between 6 and 12 months in either group. However, with a 
larger sample size, the clinical and statistical significance may change.  A limitation 
to the calculation for the DHA exposure is that we did not have enough information 
to determine exactly how much formula compared to human milk the infant was 
receiving on a day to day basis in all cases. This is discussed further in the limitations 
section.  
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Confounding Variables 
 When smoking during pregnancy, smoke exposure in the home, the number of 
children in the home, daycare attendance and pet exposure were considered, only one 
significant difference was found. Infants fed human milk were less likely to be 
exposed to smoke in the home. In regard to interpretation of the lower number of 
dermatitis episodes, it could be argued that lower smoke exposure was actually the 
important factor. As well, women in the human milk-fed group had much less asthma 
than those in the formula-fed group so genetic differences could also account for 
apparent effect of human milk to reduce dermatitis. Even though no statistically 
significant evidence was found with other environmental exposures and the 
development of URIs, dermatitis, allergy and asthma, environmental exposures are 
important to continue investigating and some of the apparent limitations should be 
accounted for when the entire cohort can be studied. There have been mixed results as 
noted above in the relationship of daycare and pet exposure to the development of 
URIs, dermatitis, allergy and asthma. It would be interesting to explore intrauterine 
environmental exposures to IgE levels in cord blood in infants as a risk factor for 
allergic sensitization, but we do not have these samples available.  
Limitations  
 One key limitation of this study is the current sample size. This is exploratory 
data for the larger study, so we anticipated this limitation from the beginning. In our 
statistical analysis, with a sample size of only 50 subjects, when the true rho was 
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equal to 0.3 we had a 59% power to reject the null hypothesis of no differences found 
in infants fed human milk greater than 16 weeks compared to infants fed human milk 
less than 16 weeks.  Based on the results we obtained with 50 children, a larger 
sample size would be able to detect more statistically and clinically significant 
differences in URIs and dermatitis in relation to human milk feeding.   
 A second limitation to this study was the difficulty in defining distinct feeding 
groups. The lack of specificity between the groups was due to the fact that 66% of the 
sample received both human milk and formula while only 8 infants were fed human 
milk exclusively during infancy. Defining the groups as infants fed human milk 
greater than or less than 16 weeks was based on previous reports that suggested 
human milk feeding for 4-6 months may be more protective against illnesses than 
terminating human milk feeding before 4 months (4, 7, 50).  Analysis using a 16-
week cutoff for human milk did reveal significance for lower dermatitis and a trend to 
later first URI. With a small sample size, it was difficult to have a large enough 
number of subjects who were fed human milk longer than 26 weeks (6 months) in 
order to compare with the subjects who were fed human milk less than 26 weeks.  
Therefore, we used 16 weeks or 4 months. The smaller subset fed human milk for 26 
weeks or more (n=22) did reveal evidence of additional protection against URIs and 
dermatitis compared to less than 6 months human milk feeding.   
In regard to calculating DHA exposure of the infants in our study, we did not 
have adequate records to determine how many ounces per day the “mixed feeders” 
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consumed of infant formula and human milk. Furthermore, if an infant in our study 
was not consuming human milk from a bottle, it was difficult to gauge how many 
ounces of human milk the infant was consuming. Therefore this made it difficult to 
calculate the amount of DHA concentration each infant was consuming. The relative 
DHA exposure was calculated by the number of weeks the infant consumed infant 
formula and/or human milk.  We have since begun asking the parent(s) or 
caregiver(s) the type of formula used, how much formula is used in each bottle, how 
many bottles are given in a day, and how many ounces the infant is drinking per 
bottle per day. For the infants receiving exclusively human milk, we now ask 
questions regarding how long the infant feeds on each breast. This information will 
make the future calculation of relative DHA exposure more reliable.  The data 
analysis for this study was based on the assumption that the formula was made as 
instructed and that the infant consumed 6 feedings per day before they were started on 
solid foods at approximately 4 to 6 months of age.   
We are aware that intrauterine exposure to DHA concentration was also 
variable. The odds are that half of the mothers in our study who breast fed for greater 
than 16 weeks and half of the mothers who breast fed for less than 16 weeks received 
the DHA supplement during pregnancy. Until the study is complete and we know 
who received the DHA supplement or the placebo, we cannot analyze the intrauterine 
DHA exposure and truly determine the effect of DHA on infant illness.  At the 
completion of the study, we can account for intrauterine DHA exposure along with 
postnatal DHA exposure from mothers’ milk and infant formula.  
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 Another limitation to this study was recording data from the medical records. 
One medical record in particular was not clear as to what was being diagnosed at one 
doctor’s visit. The physician’s progress note had a diagnosis of URI and allergic 
rhinitis at the same visit, which made it difficult to determine if it really was a URI or 
if it was allergic rhinitis. In this case, it was coded as allergic rhinitis as that seemed 
to be the final diagnosis made by the physician.    
The diagnosis for dermatitis was also not clearly indicated in the medical 
records. Atopic dermatitis is not explored as well in infants as it is in young children, 
adolescents and adults. Infant rashes appear and disappear and there is a limitation of 
detecting if the rash is from a delayed hypersensitivity reaction or something less 
relevant. The severity of the rash and sometimes the record of the duration of the rash 
were also not clearly indicated. Research cited in a review by Hahn et al. (72) 
suggested that the severity of dermatitis is more importantly linked to the “atopic 
march” than just the presence of atopic dermatitis.  
Exploratory Data for Larger Study 
  The exploratory data provides excellent guidance for how to analyze the 
larger sample size when all infants from the parent study reach 12 months of age. It 
will also be possible in future research to examine infants beyond one year of age 
because the intent is to follow children to the age of 5. The ability to record data from 
medical records to school age offers an opportunity for obtaining much more 
convincing evidence of later allergy. The “atopic march” postulates that the earlier an 
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infant is diagnosed with atopic dermatitis the greater the risk that the infant will 
develop allergies and/or asthma by the age of 3 (2). With a larger sample size from 
our parent study, and as the children in our study age, we may be able to determine if 
there is a clinical and statistical difference with an earlier onset of atopic dermatitis 
and the development of allergy and asthma in early childhood, following the pattern 
of the “atopic march.”  
 For statistical analysis, the data suggest an analysis by duration of human milk 
feeding, rather than an analysis by human milk or formula because of the prevalence 
of mixed feeding in the population.  
 Equally as important is examining DHA supplement intake during pregnancy 
to distinguish intrauterine exposure to DHA. We already know that women in our 
population have a low consumption of DHA at approximately 50 mg/day. Some of 
the intrauterine changes may have occurred through diet alone rather than 
supplementation. We will be able to determine antecedent and intrauterine DHA 
exposure from the pre-study and post-study blood samples. The diets vary greatly 
among the women in our study, and exposure to certain foods or non-exposure to 
certain foods may also have immunomodulatory effects in the fetus, however, we do 
not have 24-hour dietary recalls on women who enrolled in the study.  
The exploratory study also identified problems with recording of infant 
dietary intakes before solid food was added and provided guidance on how to gather 
data for more accurate analysis. By recording the nutrient information from dietary 
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recalls in a nutrient assessment program, NDSR (version 2008), we will have more 
accurate information regarding DHA intake for the remaining sample of 
approximately 150 infants. It may be beneficial to examine the n-6 to n-3 fatty acid 
ratio in human milk and in blood serum of infants rather than examining the DHA 
concentration alone as suggested in previous research (48, 73).  
New data suggests that vitamin D may play a role in immune function. The 
investigators who continue research with this population of women and children may 
want to look at the infants’ vitamin D status as a possible covariate when comparing 
human milk-fed infants to formula-fed infants in relation to the development of URIs, 
atopic dermatitis and allergy and asthma. Infants who receive exclusively human milk 
for a long duration of time may not be getting adequate vitamin D, especially if they 
are not given a vitamin D supplement as recommended by the American Academy of 
Pediatrics (74). Recent research has suggested that vitamin D may play a role in 
protecting infants from developing respiratory infections and enhance maturation of 
their immune function (75). In this scenario, formula-fed infants receiving vitamin D 
fortified infant formula may have an advantage compared to human milk-fed infants 
in protection from respiratory infections.  
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CHAPTER 6: SUMMARY 
 The purpose of our study was to a) determine if the duration of human milk-
feeding made a difference in the prevalence of URI, dermatitis, allergy and asthma in 
the first year of life and to b) determine if there was a relationship between intake 
from human milk and infant formula and the prevalence of URI and dermatitis in the 
first year of life.  
 The term “atopic march” has been used to describe the progression of allergy 
manifestation and asthma during early childhood and has been debated for its mixed 
results. Our results suggest that longer duration of human milk feeding decreases the 
risk of developing atopic dermatitis during the first 6 months of life. Our results also 
suggest that human milk may be more influential than infant formula in delaying the 
onset of illness.  This could protect the infant from the “atopic march” by allowing 
earlier maturation of the immune system.  
 Although our results did not show a statistically significant difference in DHA 
concentration exposure to infants and the prevalence of URIs and dermatitis, other 
studies suggest high DHA concentration exposure may lead to fewer incidences of 
URIs and dermatitis in early childhood (18).  With approximately 25% of our study 
completed, further examination of DHA concentration in serum and human milk and 
prevalence of URIs and dermatitis is needed with a larger cohort than the 50 subjects 
in our preliminary study.  We now have a better understanding for the importance of 
recording more accurate data on the fatty acid composition consumption in human 
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milk-fed and formula-fed infants. This more accurate data may show a relationship in 
the fatty acid composition consumption in both human milk-fed and formula-fed 
infants and the prevalence of URI and dermatitis episodes.  
 In conclusion, this cohort of infants will be followed until completion of the 
parent study. It is also planned to follow them throughout early childhood to 
determine if significant differences in infants who develop atopic dermatitis before 6 
months of age are more likely to develop allergy and asthma manifestations in early 
childhood.  Our findings suggest feeding human milk for a longer duration of time 
(greater than 16 weeks) may protect infants from developing atopic dermatitis in the 
first 6 months of life and offer protection from the atopic march.  
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Sample Anthropometric Data Form 
 
 
 
 
  
92 
 
INVESTIGATOR PROTOCOL RANDOM CODE 
FORM 
ID 
CARLSON HSC #10186 
  F 
ANTHROPOMETRICS 
Study Visit 1 Weight   g 
(42 days of age*)   
      Length   cm 
MO DA YEAR   
Head circumference   cm 
                      
Study Visit 2 Weight   g 
(120 days of age*)   
      Length   cm 
MO DA YEAR   
Head circumference   cm 
                      
Study Visit 3 Weight   g 
(180 days of age*)   
      Length   cm 
MO DA YEAR   
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Head circumference   cm 
                      
Study Visit 4 Weight   g 
(275 days of age*)   
      Length   cm 
MO DA YEAR   
Head circumference   cm 
                      
Study Visit 6 Weight   g 
(365 days of age*)   
      Length   cm 
MO DA YEAR   
Head circumference   cm 
                      
Study Visit 7 Weight   g 
(550 days of age*)   
      Length   cm 
MO DA YEAR   
Head circumference   cm 
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Appendix B 
Sample of Descriptive Data Form 
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INVESTIGATOR PROTOCOL RANDOM CODE 
FORM 
ID 
CARLSON HSC #10186 
  E 
INFANT FEEDING 
Visit 1 (42 days of 
age*)  
Breast 
Feeding Date started     
            Stopped     
      Frequency     
MO DA YEAR 
 
Formula 
Feeding Date started     
      Stopped     
Frequency     
Name     
                    
Visit 2 (120 days 
of age*)  
Breast 
Feeding Date started     
            Stopped     
      Frequency     
MO DA YEAR 
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 
Formula 
Feeding Date started     
      Stopped     
Frequency     
Name     
                    
Visit 3 (180 days 
of age*)  
Breast 
Feeding Date started     
            Stopped     
      Frequency     
MO DA YEAR 
 
Formula 
Feeding Date started     
      Stopped     
Frequency     
Name     
                    
Visit 4 (275 days 
of age*)  
Breast 
Feeding Date started     
            Stopped     
      Frequency     
97 
 
MO DA YEAR 
 
Formula 
Feeding Date started     
      Stopped     
Frequency     
Name     
                    
Visit 5 (300 days 
of age*)  
Breast 
Feeding Date started     
            Stopped     
      Frequency     
MO DA YEAR 
 
Formula 
Feeding Date started     
      Stopped     
Frequency     
Name     
                    
Visit 6 (365 days 
of age*)  
Breast 
Feeding Date started     
            Stopped     
98 
 
      Frequency     
MO DA YEAR 
 
Formula 
Feeding Date started     
      Stopped     
Frequency     
Name     
Visit 7 (550 days 
of age*)  
Breast 
Feeding   Date started     
            Stopped     
      Frequency     
MO DA YEAR 
 
Formula 
Feeding Date started     
      Stopped     
Frequency     
Name     
* age adjusted based on Estimated Date of Confinement  
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(EDC) 
 
INVESTIGATO
R 
PROTOCO
L RANDOM CODE 
FOR
M ID 
CARLSON 
HSC 
#10186 
  C 
DEMOGRAPHICS 
Maternal 
Education   
Paternal 
Education   
Maternal 
Smoking 
 
Before 
pregnancy 
Packs per 
day   
Date/Year 
started   
If stopped,   
100 
 
date 
 
During 
pregnancy 
Packs per 
day   
Date started   
If stopped, 
date   
 
After 
pregnancy 
Packs per 
day   
Date started   
If stopped, 
date   
Does anyone living in the baby's home smoke? 
 
N o Yes 
If yes, how many people smoke & how many ppd?  
__________________ 
List any maternal allergies: 
_________________________________________________________________ 
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Including the baby enrolled in this study, how many children 13 years of age or 
younger live in your house? 
1    2    3    4    5    6 or more 
Do any pets live in the baby's home? 
 
N
o Yes 
  If yes, how many pets?  
__________________________ 
  What kind? 
______________________________________________
__ 
Do you plan to take your baby to a daycare (facility or homecare) with other infants 
and children? 
 
N
o 
 Yes, with 1 to 5 children 
 Yes, with 6 to 10 children 
 Yes, with more than 10 children 
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Appendix C  
Human Milk Fatty Acid Analysis
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Breast milk Fatty Acid Analysis 
KUDOS  
Revised September 2008 
 
Reagents: 
0.05 M KCl 
Methanol 
Methanol + butylated hydroxytoluene (BHT) (0.05% v/v) 
Chloroform 
Internal Standard: 17:0PE (52µg/100µL)  
Glass distilled water 
Pentane 
Hexane 
Diethyl ether 
Benzene 
Transesterification (methylation)-reagent: boron trifluoride-methanol or BF3-M (14% 
w/w) 
Fatty methyl ester standards- Supelco 37 Component FAME Mix (Sigma#47885-U) 
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Equipment and Supplies: 
Extraction tubes 
Spotting tubes 
Varian 2mL screw top vials (clear vials, black caps, PTFE/Silicon liners, 12x32mm) 
 200µL, 12x32mm, flat bottom glass inserts  
Filter paper (Whatman #1: 15cm circles and 46x57 sheets) 
Glass funnels 
Pasteur pipettes 
Automatic pipettes in range of volumes 
Centrifuges 
Nitrogen evaporator with water bath that can be temperature controlled 
Gas chromatograph 
Developing tank 
Heating block (dry bath) 
Hamilton syringes (100µL for spotting and concentrating FAME’s and 10µL for 
injecting into GC) 
Ice bucket 
105 
 
Vortexer 
EXTRACTION (Smuts et. al, 2003): 
1. Pipet 4mL of methanol+ BHT into clean 15mL extraction tubes. 
2. Add 500µL breast milk cap, and immediately vortex for a few seconds. 
3. Add 100µL internal standard (17:0 PE) and vortex. 
4. Add 8mL Chloroform and vortex 15 minutes. 
5. Transfer contents through a funnel lined with filter paper (Whatman #1) into a 
clean extraction tube. 
6. Add 1.6mL 0.05M KCl and vortex for 10 seconds. 
7. Centrifuge for 5 minutes at 750 r.p.m. and then using a clean Pasteur pipette 
discard upper phase into appropriate hazardous waste bottle. 
8. Evaporate the lower phase in a water bath at 35°C under nitrogen.  
9. [Add 1-2mL benzene and re-evaporate if small amounts of water remain in 
sample].  
TRANSMETHYLATION 
10. When extract is completely dry, add 0.25mL BF3 14% solution in methanol, 
0.2mL Benzene, and 0.55mL Methanol.  
11.  Layer each tube with N2 and place on ice until all samples are finished. 
12.  Tighten caps and place in dry bath at 100°C for 30 minutes. 
13. After 1-2 minutes retighten caps as they tend to loosen during heating. 
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14. After transmethylation is complete, immediately place tubes on ice.  When 
tubes are very cool, open and add 1mL of distilled H2O and 2 mL pentane. 
15. Vortex for 1-2 minutes to extract fatty acid methyl esters (FAME) into the 
pentane phase, then centrifuge for 5 min. at 800 r.p.m. 
16. Transfer the upper phase (pentane) with a Pasteur pipet to a Varian 2mL vial.   
17. Concentrate the FAME under a stream of N2. 
18. When completely dry, add 150µL of dichloromethane to vial. Swirl tube to 
catch FAME on all sides and then transfer with Hamilton syringe to a 200 µL, 
12x32mm, flat bottom glass insert.  Place the glass insert inside of the 2 mL 
vial and cap with a Teflon-lined cap. 
      19.  Place sample in GC auto-sampler tray to inject or in freezer until it can be    
 analyzed.  
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Appendix D 
Plasma and Red Blood Cell Fatty Acid Analysis  
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Plasma and Red Blood Cell Fatty Acid Analysis 
(Total Phospholipids): KUDOS  
Revised February 2009 
 
Reagents: 
0.05 M KCl 
Methanol 
Methanol + butylated hydroxytoluene (BHT) (0.05% v/v) 
Chloroform 
Internal Standard: 17:0PE (52µg/100µL)  
Glass distilled water 
Pentane 
Hexane 
Diethyl ether 
Benzene 
Transesterification (methylation)-reagent: boron trifluoride-methanol or BF3-M (14% 
w/w) 
Fatty methyl ester standards- Supelco 37 Component FAME Mix (Sigma#47885-U) 
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Equipment and Supplies: 
Extraction tubes 
Spotting tubes 
Varian 2mL screw top vials (clear vials, black caps, PTFE/Silicon liners, 12x32mm) 
 200µL, 12x32mm, flat bottom glass inserts  
Filter paper (Whatman #1: 15cm circles and 46x57 sheets) 
Glass funnels 
Pasteur pipettes 
Automatic pipettes in range of volumes 
Centrifuges 
Nitrogen evaporator with water bath that can be temperature controlled 
Gas chromatograph 
Developing tank 
Heating block (dry bath) 
Hamilton syringes (100µL for spotting and concentrating FAME’s and 10µL for 
injecting into GC) 
Ice bucket 
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Vortexer 
BLOOD PREP PROCEDURE (Dennis Hoffman): 
1. Centrifuge blood (4°C) at 30,000g-min [3000 x g x 10 minutes i.e., 3,600 
RPM] in Ependorf 5804 R refrigerated bench-top centrifuge with an A-4-44 
swing-bucket rotor. 
 
2. Pipet plasma to a 1.5mL, 10.8x 40.6mm plastic micro centrifuge tube (Fisher 
#05-408-129). 
 
3. Pipet  buffy coat to a 1.5mL, 10.8x 40.6mm plastic micro centrifuge tube 
(Fisher #05-408-129). 
 
4. Pipet RBC to a 1.5mL, 10.8x 40.6mm plastic micro centrifuge tube (Fisher 
#05-408-129). 
 
5. Flush tubes with N2, cap, and store in (-80°C). 
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EXTRACTION (Smuts et. al, 2003): 
1. Pipet 4mL of methanol+ BHT into clean 15mL extraction tubes. 
2. Add 500µL RBC’s or Plasma, cap, and immediately vortex for a few seconds. 
3. Add 100µL internal standard (17:0 PE) and vortex. 
4. Add 8mL Chloroform and vortex.  Vortex 15 minutes for RBC’s and 10 
minutes for Plasma. 
5. Transfer contents through a funnel lined with filter paper (Whatman #1) into a 
clean extraction tube. 
6. Add 1.6mL 0.05M KCl and vortex for 10 seconds. 
7. Centrifuge for 5 minutes at 750 r.p.m. and then using a clean Pasteur pipette 
discard upper phase into appropriate hazardous waste bottle. 
8. Evaporate the lower phase in a water bath at 35°C under nitrogen.  
9. [Add 1-2mL benzene and re-evaporate if small amounts of water remain in 
sample].  
SEPARATION OF TOTAL PHOSPHOLIPIDS (Smuts et. al, 2003): 
10. When extract is completely dry, dissolve in 100µL cold dichloromethane and 
place immediately on ice until ready to spot plates.   
11. When plates have been heated for at least 20 minutes at 120°C, take out of 
oven and cool.   Spot 100µL for analysis of total phospholipids. 
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12. Place the spotted plate immediately in the TLC chamber containing the 
developing solvent 80:20:1 Hexane: Ether: Acetic Acid and that has been 
lined with filter paper. 
13. Allow the solvent front to run to the top of the plate and then remove from 
TLC chamber to dry.  
14. Identify phospholipid line (it is the same line as the spotting line). Remove the 
gel containing the lipid fraction of interest with a single edge razor blade onto 
weighing paper.  Carefully transfer the gel to a clean 15mL extraction tubes 
containing 1 mL cold BF3 14% solution in methanol (Sigma # B1252). 
TRANSMETHYLATION 
15.  Layer each tube with N2 and place on ice until all samples are finished 
spotting. 
16.  Tighten caps and place in dry bath at 100°C for 10 minutes. 
17. After 1-2 minutes retighten caps as they tend to loosen during heating. 
18. After transmethylation is complete, immediately place tubes on ice.  When 
tubes are very cool, open and add 1mL of distilled H2O and 2 mL pentane. 
19. Vortex for 1-2 minutes to extract fatty acid methyl esters (FAME) into the 
pentane phase, then centrifuge for 5 min. at 800 r.p.m. 
20. Transfer the upper phase (pentane) with a Pasteur pipet to a Varian 2mL vial.   
21. Concentrate the FAME under a stream of N2. 
22. When completely dry, add 70µL of dichloromethane to vial. Swirl tube to 
catch FAME on all sides and then transfer with Hamilton syringe to a 200 µL, 
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12x32mm, flat bottom glass insert.  Place the glass insert inside of the 2 mL 
vial and cap with a Teflon-lined cap. 
23.  Place sample in GC auto-sampler tray to inject or in freezer until it can be 
analyzed.  
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Appendix E 
URI and Dermatitis Episodes by 3 Month Interv;als by Duration of Human Milk 
Feeding  
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 URI episodes diagnosed between 0 and 3 months of age.  
 
 URI episodes diagnosed between 3 and 6 months of age.  
  Number of URI Episodes 3-6 Months of Age 
  0 1 2 3 Total 
Fed Human Milk <16 
weeks 16 8 1 0 25 
Fed Human Milk >16 
weeks 16 5 2 2 25 
Total 32 13 3 2 50 
 
 URI episodes diagnosed between 6 and 10 months of age.  
  Number of URI Episodes 6-10 Months of Age 
  0 1 2 Total 
Fed Human Milk <16 
weeks 13 10 2 25 
Fed Human Milk >16 
weeks 10 13 2 25 
Total 23 23 4 50   
 
 URI episodes diagnosed between 10 and 12 months of age.  
  Number of URI Episodes 10-12 Months of Age 
  0 1 Total 
Fed Human Milk <16 
weeks 21 4 25 
Fed Human Milk >16 
weeks 21 4 25 
Total 42 8 50 
 
  Number of URI Episodes 0-3 Months of Age 
  0 1 2 Total 
Fed Human Milk <16 
weeks 18 6 1 25 
Fed Human Milk >16 
weeks 19 6 0 25 
Total 37 12 1 50 
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Dermatitis by 3 month Intervals by Duration of Human Milk Feeding 
Dermatitis episodes diagnosed between 0 and 3 months of age. 
  
Number of Dermatitis Episodes 0-3 Months of 
Age 
  0 1 Total 
Fed Human Milk <16 
weeks 21 4 25 
Fed Human Milk >16 
weeks 23 2 25 
Total 44 6 50 
 
Dermatitis episodes diagnosed between 3 and 6 months of age.  
  Number of Dermatitis Episodes 3-6 Months of Age 
  0 1 2 Total 
Fed Human Milk <16 
weeks 18 7 0 25 
Fed Human Milk >16 
weeks 21 3 1 25 
Total 39 10 1 50 
 
Dermatitis episodes diagnosed between 6 and 10 months of age.  
  Number of Dermatitis Episodes 6-10 Months of Age 
  0 1 2 Total 
Fed Human Milk <16 
weeks 20 5 0 25 
Fed Human Milk >16 
weeks 20 3 2 25 
Total 40 8 2 50 
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Dermatitis episodes diagnosed between 10 and 12 months of age.  
  
Number of Dermatitis Episodes 10-12 Months of 
Age 
  0 1 Total 
Fed Human Milk <16 
weeks 23 2 25 
Fed Human Milk >16 
weeks 23 2 25 
Total 46 4 50 
 
 
